RESI CONFERENCE

REDEFINING EVERY STAGE OF INVESTMENT *SEED TO EXIT*

BOSTON 2025

September 17: Westin Copley Place, Boston | September 18-19: Virtual Partnering



PRESENTED BY

LIFE SCIENCE NATION
Connecting Products, Services & Capital

ONSITE GUIDE

Capital investors, licensing partners, fundraising CEOs, and service providers

Make a Compelling Connection

TITLE SPONSORS

POLSINELLI
What a law firm *should* be.™

BioMeta
Advancing your discovery

LONGEVITY GLOBAL

RESIConference.com | Westin Copley Place

#RESI #RESIBOSTON

RESI 2025-26 CONFERENCE SERIES

RESI LONDON 2025

DEC 4: 11 CAVENDISH SQUARE, LONDON
DEC 8-9: VIRTUAL PARTNERING

RESI JPM 2026

JAN 12-13: SAN FRANCISCO MARRIOTT MARQUIS
JAN 14, 19 & 20: VIRTUAL PARTNERING

RESI EUROPE 2026

MAR 23: LISBON, PORTUGAL
MAR 24-25: VIRTUAL PARTNERING

Take $100 off with discount code **RESI100** for future RESIs.

For more information about our future events,
visit our website RESIConference.com
or contact us at RESI@lifesciencenation.com.

CONTENT

RESI BOSTON JUNE 2025

WELCOME TO RESI

Welcome to RESI Boston – Redefining Every Stage of Investment

Thank you for joining us at RESI Boston, taking place at the Westin Copley Place. Life Science Nation (LSN) is proud to host this dynamic gathering of global investors, licensing partners, and innovators representing every stage of the healthcare investment landscape.

RESI Boston September offers a full day of programming designed to maximize exposure, engagement, and strategic opportunity. Each hour features investor panels, two concurrent tracks of the Innovator's Pitch Challenge (IPC), and interactive workshops. The IPC highlights a diverse group of presenting companies across biotech, medtech, diagnostics, and digital health, who pitch live to investor judges. Attendees can participate by voting with RESI Cash for their favorite companies, adding an interactive and competitive element to the experience. Be sure to explore the exhibit hall in the Essex Ballroom to connect with these innovators and learn more about their technologies.

Throughout the day, RESI attendees will also have the opportunity to engage with tech hubs and service providers that play an essential role in supporting company growth and fundraising efforts. These organizations are available through exhibits, panel discussions, and educational sessions. Our networking receptions provide additional space for fostering new relationships and expanding professional networks.

New to RESI Boston September, Longevity Global, will host the track Innovation and Investment to Beat Aging and Age-Related Disease. This program will feature talks by noted longevity experts, leaders of successful aging-related startups, investors in the longevity space, and longevity thought leaders. It will also include a pitch competition that puts companies in front of an exceptional portfolio of investors, with prizes for finalists that will help advance their businesses. Attendees will have the opportunity to meet and connect with top investors and founders in the aging sector as well as across the broader biotech industry.

We extend our sincere thanks to this year's sponsors:

Title Sponsors – Biometas, Polsinelli, Longevity Global

Gold Sponsor – Medmarc

Silver Sponsors – Trinet, Mosaic Biosciences, DLA Piper, Genaxis

Their partnership is instrumental in creating the connections and collaborative environment that define RESI.

RESI's partnering platform continues to be the foundation of this conference, matching companies with capital, licensing, and channel partners through curated 1:1 meetings. In-person partnering takes place today, with additional opportunities to connect through ad hoc networking, panels, and receptions.

We look forward to a productive and impactful day of innovation and investment.

Sougato Das
President and Chief Operating Officer
Life Science Nation

LIFE SCIENCE NATION
Connecting Products, Services & Capital

THE WESTIN COPLEY PLACE

3RD FLOOR

WiFi: RESI_Conference
PW: resi2025

8:00 AM - 5:00 PM: Partnering Meetings (Essex Ballroom & Staffordshire)

7:00 AM - 8:00 AM: Breakfast Buffet (Foyer)

9:00 AM - 5:00 PM: Investor Panels (St. George A)

9:00 AM - 5:00 PM: Innovator's Pitch Challenge Tracks 1 & 2 (St. George B & C)

9:00 AM - 5:00 PM: Workshops (St. George D)

9:00 AM - 5:00 PM: Longevity Global (Essex North Center & East)

12:00 PM - 1:00 PM: Lunch (Foyer)

5:00 PM - 7:00 PM: Cocktail Reception (Foyer)

EXHIBIT TABLES

Location: Foyer

MEDMARC LIFE SCIENCES INSURANCE	LIFE SCIENCE NATION Connecting Products, Services & Capital	BIOTECH GATE GLOBAL DATABASE	Lab Central
Table #1	Table #2 3 4	Table #5	Table #6
GENAXIS	DLRC	Symeres Making Molecules Matter. Together.	POLSINELLI What a law firm *should* be.™
Table #7	Table #8	Table #9	Table #10
DLA PIPER	trinet	mosaic	Boulder IQ Innovation to Quality
Table #11	Table #12	Table #13	Table #15
CAMBRIDGE SCIENTIFIC / CAMBRIDGE SCIENTIFIC LABS	EGC EVA GARLAND CONSULTING	ZUBER LAWLER Global Legal Solutions for Visionary Clients®	LONGEVITY GLOBAL
Table #16	Table #17	Table #18	Table #19
	CDD VAULT Complexity Simplified	QUARTZY	
	Table #20	Table #21	

INNOVATOR'S PITCH CHALLENGE

Location: Essex Ballroom

EXOSYSTEMS	LAON iMEDI	CURLIM	Elastrin The Only Therapy Proven to Reverse Arterial Calcification	KORTUC
Table #1	Table #2	Table #3	Table #4	Table #5
ChromaTan Continuous Column-Free Chromatography	TISSUE FORM	MLA DIAGNOSTICS	TESORO IMAGING	SENSA NEUROSCIENCE
Table #6	Table #7	Table #8	Table #9	Table #10

INNOVATOR'S PITCH CHALLENGE

Location: Essex Ballroom

Chronicle	DEEPSONBIO	RadaHaim	BILIX	ORGANOPlus
Table #11	Table #12	Table #13	Table #14	Table #15
BE Therapeutics	ReEngage Therapeutics	Treasure biosciences	RONAWK	MKP THERAPEUTICS
Table #16	Table #17	Table #18	Table #19	Table #20
AlgoDx	GIBionics NextGen Medical Devices	Kare	INSTA DIAGNOSTICS	THRIVE BIOSCIENCE
Table #21	Table #22	Table #23	Table #24	Table #25
PERSISTABIO	Geneia	BMI OrganBank	ONCODEA	inomagen
Table #26	Table #27	Table #28	Table #29	Table #30
B4 RNA	ISOTECH	PreTeL	nSight Surgical	Bio Therapeutics
Table #31	Table #32	Table #33	Table #34	Table #35
Ignota Labs	pacDNA Tx	TroGen THERAPEUTICS	blend	medovation CLINICAL RESEARCH
Table #36	Table #37	Table #38	Table #39	Table #40
NeuroVirt	WatchRx, Inc. HEALTH. DIGNITY. INDEPENDENCE	Gardn Bio	Numiera Therapeutics	adipo
Table #41	Table #42	Table #43	Table #44	Table #45

ONCOVITA	alleviate	TRBO TR Beta Oncology	Genialis
Table #46	Table #47	Table #48	Table #49
manabio Programmable drug delivery	Embrace Prevention Care	gutz analytics	Spatial Surgical
Table #50	Table #51	Table #52	Table #53

AGENDA

8:00 AM – 5:00 PM: Onsite Partnering (Essex Ballroom + Staffordshire)
7:00 AM – 8:00 AM: Breakfast Buffet (Foyer)

	Innovator's Pitch Challenge			
Investor Panels (St. George A)	**Track 1 (St. George B)**	**Track 2 (St. George C)**	**Workshops (St. George D)**	**LONGEVITY GLOBAL (Essexeast & center)**
9:00 - 9:50 AM				
IMPACT INVESTORS & VENTURE PHILANTHROPY *The Role of Impact Investing in the Healthcare Ecosystem*	**SESSION #1 THERAPEUTICS**	**SESSION #8 MEDICAL DEVICES**	**NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS**	**9:00 am** **Opening Remarks** **9:15 am** Eric Morgen (Co-founder, BioAge) Keynote **10:00 am** **Raghav Seghal** (Yale) **10:25 am** **Christin Glorioso, MD PHD** (CEO, NeuroAge, Longevity Global) **10:50 am** **Spring Behrouz** (Vincere Bio) Mitochondrial Aging and Longevity Fundraising **11:15 am** **Pharma Chat** **Suguna Rachakonda** (VP, Insilico) **Jon McClain** (Executive Director, Lilly)
10:00 - 10:50 AM				
MENTAL & BEHAVIORAL HEALTH *Investing in Solutions for Higher Quality of Life and Wellbeing*	**SESSION #2 THERAPEUTICS**	**SESSIONE #9 MEDICAL DEVICES & DIAGNOSTICS**	**TALES FROM THE ROAD** *Biotech and MedTech Innovators on their Fundraising Journey*	
11:00 - 11:50 AM				
ONCOLOGY INNOVATION *Latest Scientific Breakthroughs and Future Outlook*	**SESSION #3 MEDICAL DEVICES**	**SESSION #10 DIGITAL HEALTH**	LIFE SCIENCE NATION Connecting Products, Services & Capital **LSN BD ASSIST** *Your Global Matching and Partnering Engine*	
12:00 - 1:00 PM: Lunch Break (Foyer)				
1:00 - 1:50 PM				
CORPORATE VC *Venture and Innovation Arms Making Strategic Investments*	**SESSION #4 THERAPEUTICS**	**SESSION #11 MEDICAL DEVICES**	MSQ VENTURES **AI-DRIVEN TRANSFORMATION IN LIFE SCIENCES**	**1:00 pm** **Sharon Rosenzweig-Lipson** (Life Biosciences) Keynote **1:45 pm** **Umbereen S. Nehal, MD, MPH, MBA** (Founder, HER Heard, MIT) Women's Health Interventions for Longevity **2:10 pm** **Ethan Berg** (Founder, Winthrop Estate) The Case for Investing in Longevity **2:15 pm** **Investor Panel** **Sally Wang** (XPanse Ventures) **Ruta Laukien** (US Capital, GrayBella Capital) **Fiona Miller** (quadraScope) **3:00 pm** **Innovation Panel** **M: Tom Zuber, MPP, JD** (Zuber Lawler), **Frank Gerratana, JD** (Partner, Calyx Law), **Shane Hegarty** (AXONIS), **Jay Luthar, MD** (Founder, Lutanen Health) **3:45 pm** **Pitch Competition - Series A** **4:45 pm** **Pitch Competition Winners Announced** - Daniel Dacey & The Engine
2:00 - 2:50 PM				
DIAGNOSTICS *Investing in Innovations for Preventative and Personalized Care*	**SESSION #5 R&D AND ENABLING TECHNOLOGIES**	**SESSION #12 DIGITAL HEALTH**	VENTURE VALUATION GLOBAL VALUATION SERVICES **COMPANY VALUATION FOR FUNDRAISING**	
3:00 - 3:50 PM				
PARTNERING WITH BIG PHARMA *What Startups Need to Know to Get on Big Pharma's Radar*	**SESSION #6 THERAPEUTICS**	**SESSION #13 DIAGNOSTICS**	mosaic **ACCELERATING EARLY-STAGE DRUG DISCOVERY**	
4:00 - 4:50 PM				
FAMILY OFFICES *Perspectives on Early-Stage Investments*	**SESSION #7 THERAPEUTICS**	**SESSION #14 R&D AND ENABLING TECHNOLOGIES**	LIFE SCIENCE NATION Connecting Products, Services & Capital **BRANDING & MESSAGING OVERVIEW**	
5:00 - 7:00 PM: Cocktail Reception - IPC Winners Announced (Foyer)				

POLSINELLI®

What a law firm *should* be.™

Polsinelli's nationally recognized multidisciplinary team provides life sciences and health care clients with a full-service approach through every stage of the corporate lifecycle, from start-up to growth to liquidity. We counsel clients on entity formation, pre-seed/seed/venture stage financings, patent prosecution and strategy (including Freedom to Operate opinions), in-licensing and out-licensing, FDA compliance, health care reimbursement and litigation (including Hatch-Waxman and ITC), collaborations, mergers and acquisitions and public offerings/SEC compliance. We have deep industry experience in all of the life science verticals — including biotech, medical devices, pharmaceuticals, digital health, food and agriculture — as well as health care — including hospitals and health systems, pharmacies, behavioral health, home health and hospice, infusion therapy, and long-term care/assisted living facilities.

We look forward to the opportunity to connect!

CAPABILITIES

Business

Health Care

Intellectual Property

Litigation

Labor & Employment

Real Estate

Regulatory

Am Law 100 firm | 1,200+ attorneys nationwide
25+ offices from LA to NY | 170+ services/industries

LONGEVITY GLOBAL @RESI BOSTON

Longevity Global is coming to RESI! We are curating a Longevity Track for this revered event that brings investors and startups together to learn, meet, and make things happen!

AGENDA

Subject to Change

Wednesday, September 17th

8:00 am **Coffee & Networking**
9:00 am **Opening Remarks**
9:15 am **Eric Morgen (Co-founder, BioAge)**
Keynote
10:00 am **Raghav Seghal (Yale)**
10:25 am **Christin Glorioso, MD PHD (CEO, NeuroAge, Longevity Global)**
10:50 am **Spring Behrouz (Vincere Bio)**
Mitochondrial Aging and Longevity Fundraising
11:15 am **Pharma Chat**
Suguna Rachakonda (VP, Insilico)
Jon McClain (Executive Director, Lilly)
12:00 pm **Lunch Break**
1:00 pm **Sharon Rosenzweig-Lipson (Life Biosciences)**
Keynote
1:45 pm **Umbereen S. Nehal, MD, MPH, MBA (Founder, HER Heard, MIT)**
Women's Health Interventions for Longevity
2:10 pm **Ethan Berg (Founder, Winthrop Estate)**
The Case for Investing in Longevity
2:15 pm **Investor Panel**
Sally Wang (XPanse Ventures)
Ruta Laukien (US Capital, GrayBella Capital)
Fiona Miller (quadraScope)
3:00 pm **Innovation Panel**
M: Tom Zuber, MPP, JD (Zuber Lawler)
Frank Gerratana, JD (Partner, Calyx Law)
Shane Hegarty (AXONIS)
Jay Luthar, MD (Founder, Lutanen Health)
3:45 pm **Pitch Competition**
Series A
4:45 pm **Pitch Competition Winners Announced**
Daniel Dacey & The Engine
5:00 pm **RESI Cocktail Hour**
Wine and Hors d'oeuvres

Longevity Global

Connecting longevity researchers, entrepreneurs, and investors to create community and collaboration — a non-profit with chapters in SF, NYC, SD, BOS, UAE, and MIA.

Apply in 1 minute

longevitygl.org/join

Why become a member?

Curated community

Join a vetted network of top researchers, founders, clinicians, and investors focused on advancing longevity and healthspan.

Events & programs

From the Longevity Summit at the Buck Institute to chapter meetups, talks, and socials — opportunities to learn, collaborate, and connect.

Intros, perks & opportunities

Warm introductions through our community platform, discount marketplace, jobs board, and partner programs for members.

Membership options

Basic
FREE

Invitations to our events, Slack access, and a community of like-minded professionals.

Sustaining Student
$60/yr

Everything in Basic + free/discounted events & products, and warm intros via our community platform.

Sustaining
$120/yr

Everything in Basic + free/discounted events & products, and warm intros via our community platform.

Ready to join?
Apply now — it takes about one minute.

longevitygl.org/join

hello@longevitygl.org

MEDMARC®
LIFE SCIENCES INSURANCE

Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: MedTechLifeSci@medmarc.com
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

LEARN MORE
medmarc.com

SPONSORS & EXHIBITORS

TITLE SPONSORS

POLSINELLI
What a law firm *should* be.™

BioMeta
Advancing your discovery

LONGEVITY GLOBAL

GOLD SPONSOR

MEDMARC®
LIFE SCIENCES INSURANCE

SILVER SPONSORS

trinet™

mosaic

DLA PIPER

GENAXIS

EXHIBITORS

EGC
EVA GARLAND CONSULTING

BIOTECH GATE
GLOBAL DATABASE

CAMBRIDGE SCIENTIFIC
CAMBRIDGE SCIENTIFIC LABS

Boulder iQ
Innovation to Quality

DLRC

ZUBER LAWLER
Global Legal Solutions for Visionary Clients®

Symeres
Making Molecules Matter. Together.

Lab | Central

CDD VAULT®
Complexity Simplified

RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION

LIFE SCIENCE NATION
Connecting Products, Services & Capital

Life Science Nation (LSN)

LSN has built a global partnering ecosystem connecting early-stage healthcare companies with capital investors, licensing partners, and strategic collaborators. Our resources accelerate fundraising by bridging the gap between innovators and the right partners.

Table #3&4

Key Resources

- GPC Platform + RESI Conference Series: Match with investors and partners by product, stage, and allocation needs across Drugs, Devices, Diagnostics, and Digital Health.
- Partner Network: Includes service providers, tech hubs, and agencies that power early-stage life sciences.
- Three Components: Investor & Licensing Partner Database integrated with Salesforce CRM, RESI Partnering Events, and Entrepreneurial Education.

GPC Global Partnering Campaign

Global Partnering Campaign (GPC)

The GPC combines LSN's investor/licensing database with Salesforce CRM. Subscribers receive a vetted Global Target List (GTL) of likely partners organized into priority tiers:

- Tier 1: Exact mandate fit
- Tier 2: Opportunistic investors seeking compelling assets
- Tier 3: Potential fits based on recent activity

Profiles update daily and integrate with CRM to track outreach, materials shared, notes, and investor pipeline reporting.

LSN BD ASSIST

LSN BD Assist

BD Assist is LSN's full-service investor outreach and meeting management solution. We handle the time-consuming work of booking and managing meetings so you can focus on the science.

Table #2

What BD Assist Delivers

- AI-optimized messaging for outreach
- Prioritized partner targeting
- Coordinated outreach campaigns
- Confirmed investor meetings synced to your CRM

With over a decade of experience teaching startups how to craft their story and secure funding, LSN combines trusted methodology with hands-on execution. Results speak for themselves: 90% of companies in our Australian accelerator cohort secured funding or partnerships.

If you're raising capital or licensing in the next 12 months, BD Assist is your turnkey solution for launching a global campaign without building an in-house BD team.

Contact us at salescore@lifesciencenation.com to get started.

LIFE SCIENCE NATION PUBLICATIONS

LSN Publications

Life Science Nation's (LSN) publications offer a current dialogue for early-stage (seed to series A), life science, fundraising companies to sharpen the skills needed to create a compelling fundraising campaign. These publications include education on how to increase fundraising and marketing efforts for their organization or affiliated startups, expert interviews, event announcements, and active investor mandates. Subscribe and stay up-to-date with meaningful insight into raising capital in the life science industry.



NEXT PHASE»

SPONSORS & EXHIBITORS

POLSINELLI
What a law firm *should* be.™

Table 10

Polsinelli is an Am Law 100 firm with more than 1,200 attorneys in over 25 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on life sciences, health care, real estate, finance, technology, and private equity.

BioMetas
Advancing your discovery

BioMetas: Supporting the Next Generation of Therapeutic Startups
BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.

LONGEVITY GLOBAL

Table #19

Longevity Global is a non-profit membership community dedicated to connecting entrepreneurs, investors, and scientists in the longevity space to create collaborations. We have chapters that host events around the world including in Boston, NYC, San Francisco, San Diego, Miami, Switzerland, and the UAE. Our largest event is the Longevity Summit held at the Buck Institute in the San Francisco Bay Area Dec 9-10th. You can sign up to be a member and register for events on our website https://longevitygl.org/. You might just meet your next co-founder, investor, hire, or friend at one of our events or online on our platform. Basic membership is free.

MEDMARC®
LIFE SCIENCES INSURANCE

Table 1

Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan. (703) 652-1360

GENAXIS

Table 7

Genaxis is a leading accelerator dedicated to supporting deep-tech and biotech startups. We deliver customized acceleration programs, strategic mentoring, and global investor access to help companies grow beyond their local markets. With expertise in investment readiness, cross-border collaboration, and global market entry, Genaxis equips entrepreneurs with the tools and networks they need for sustainable growth. As a Silver Sponsor of RESI Boston 2025, we are committed to connecting innovative startups with global life science investors, fostering collaboration between Korea and the world. Our mission is to empower founders to achieve impactful innovation, create long-term value, and strengthen the global startup ecosystem.

trinet™

Table 12

TriNet (NYSE: TNET) provides small and medium-size businesses (SMBs) with full-service HR solutions tailored by industry. To free SMBs from HR complexities, TriNet offers access to human capital expertise, benefits, risk mitigation and compliance, payroll and real-time technology. From Main Street to Wall Street, TriNet empowers SMBs to focus on what matters most—growing their business.

SPONSORS & EXHIBITORS

Mosaic is a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. Mosaic teams provide comprehensive, end-to-end discovery services, including program assessment and strategy development; program management; antibody discovery and optimization; protein production, purification, and characterization; protein engineering; biochemical and cellular assay development; formulation, stability and developability studies; bioanalytical (PK and PD) assay development; and clinical candidate-validating pharmacology. Mosaic partners include biopharmaceutical companies, startup companies, and University seed and venture capital funds. For more information, please visit www.mosaicbio.com

Table 13

DLA Piper is a global law firm helping our clients achieve their goals wherever they do business. Our pursuit of innovation has transformed our delivery of legal services. With offices in the Americas, Europe, the Middle East, Africa and Asia Pacific, we deliver exceptional outcomes on cross-border projects, critical transactions and high-stakes disputes. Every day we help trailblazing organizations seize business opportunities and successfully manage growth and change at speed. Through our pro bono work and community investment around the world, we help create a more just and sustainable future. Visit dlapiper.com to discover more.

Table 11

Eva Garland Consulting (EGC), helps innovators leverage non-dilutive funding to accelerate their technology development. By connecting our clients with the resources they need to support scientific advancement, EGC seeks to break down the barriers that exist in translating great scientific discoveries into solutions that can solve our society's most pressing problems. Our Ph.D. Grant Writing Specialists provide a highly efficient and effective approach to obtaining non-dilutive funding. EGC has helped it clients secure and manage over $2 Billion in grants and contracts from government agencies including NIH, DARPA, BARDA, ARPA-H, DOD, CDMRP, MTEC, NSF, DOE, CIRM as well as from Private Foundations. EGC uniquely offers both Scientific and Accounting & Compliance expertise, thus supporting the full lifecycle of our clients' innovative research and development in the United States and worldwide.

Table #17

Boulder iQ is an expert contract consulting firm providing all the services a life science company needs to get its product to market. With expertise in regulatory, quality, product development, manufacturing and contract sterilization, our single-source solution speeds the product development and regulatory submissions process. Our mission is to expedite your pathway to market, with emphasis on the sterilization validation process. We offer comprehensive sterilization solutions, including Ethylene Oxide (EO) and Chlorine Dioxide (CD) sterilization, each with its unique benefits. Recognizing the need for a seamless transition from product development to market, we also offer assembly, packaging, and packaging validation to effectively bridge the gap and provide a holistic solution for our clients.

Table #15

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

Table #5

Cambridge Scientific is a service company specializing in the sale of life science equipment. We offer equipment to the biotech and pharmaceutical industry including startups, universities, and hospitals, both nationally and internationally. Additionally, we operate our own Biotech Incubator called Cambridge Scientific Labs, where we provide cost-effective, fully furnished shared and private lab suites, complete with equipment provided by Cambridge Scientific.

Table #16

SPONSORS & EXHIBITORS

Table #8

The pathway to market is complex, but DLRC makes it simpler. With offices in the UK, Germany, and the US, and over 1,000 years of combined regulatory experience, we support clients from top pharma to start-ups with strategies covering the full lifecycle of medicinal products and medical devices. Our expert team has served 130+ companies worldwide, offering global regulatory advice, gap analysis, expedited pathways, EU CTR transition planning, and health authority engagement, as well as managing clinical trial applications, marketing authorisations, medical writing, and lifecycle operations. We also provide representation as US agent, EU authorised/ legal representative, and SME/ODD/MAH holder. Recognised with the King's Award for Enterprise and TOPRA Regulatory Excellence, DLRC is a trusted partner for maximising product potential.

ZUBER LAWLER
Global Legal Solutions for Visionary Clients®

Table #18

Zuber Lawler is one of the most selective law firms in the United States, with 40-plus attorneys representing clients throughout the world from offices in Chicago, Columbus, Denver, Los Angeles, New York, Phoenix, and Seattle. Our clients include more than 15 Fortune 500 clients, as well as funds and government entities. Primary practice areas include IP, regulatory work, class actions, and M&A, both domestically and across languages and borders throughout the world. Zuber Lawler has attorneys trained in both common and civil law systems. Our attorneys work in Armenian, Chinese, Farsi, French, German, Italian, Japanese, Portuguese, Russian, Spanish, and Taiwanese, among other languages.

Lab | Central

Table #6

LabCentral provides unmatched infrastructure, expert support, and a vibrant community to advance innovative life sciences startups. Headquartered in Cambridge, MA, we've built our network to support your science, business, and people as you grow from early-stage research through scale-up, process development, and beyond. To date, LabCentral has fostered the growth of over 314 companies that have raised $20.6B in funding, leading to 158 clinical trials with 15,688 patients enrolled. As a 501(c)(3) non-profit with established industry partnerships, LabCentral provides the space, equipment, and connections that founders and startups need to succeed.

Symeres
Making Molecules Matter. Together.

Table #9

Symeres is a transatlantic partner for small-molecule drug discovery and development, guiding programs from the first spark of discovery through to clinical development and manufacturing.
With eight locations across Europe and North America and more than 30 years of industry experience, we combine deep scientific expertise with an agile, collaborative mindset. Our integrated services span hit identification, medicinal chemistry, ADME-Tox, in vitro biology, and process development through to GMP manufacturing. This breadth enables us to seamlessly connect disciplines, accelerate decision-making, and keep programs moving with clarity and confidence. At Symeres, we pride ourselves not only on our technical excellence but also on how we work: open, responsive, and personally invested in every project. Clients choose us for our capabilities and stay for our care, continuity, and commitment to making complex science feel simple. Work with a partner who moves with you.

CDD VAULT®
Complexity Simplified

Table #20

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface. CDD Vault helps scientists register entities, track inventory, manage bioassay data, capture experiments, calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. It also functions as an Electronic Laboratory Notebook (ELN) to capture and share experimental results. CDD Vault is differentiated through its intuitive design, superior performance, and workflows for secure, collaborative data sharing capabilities. CDD was founded in 2004 and presently serves thousands of researchers doing drug discovery all around the world. Learn more at www.collaborativedrug.com

QUARTZY

Table #21

Quartzy is the leading operations platform purpose-built for scaling biotech companies. From Idea to IPO, we help you streamline inventory, ordering, and procurement in one place, so your team can spend less time chasing supplies and more time hitting scientific milestones. Quartzy combines workflow tools with a built-in marketplace to simplify operations, ensure compliance, and stretch your capital further as you grow.

MEDIA PARTNERS

Want to become a RESI Media Partner? Contact us at Marketing@lifesciencenation.com



ABOUT THE BOOK

A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge.

The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies, using a consistent message to achieve compelling results from a fundraising campaign. It teaches you how to aggregate a list of potential global investors that are a fit for your company's products and services. Then it explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.

Raising capital is not a one-time event. It must be an ongoing part of your business strategy. ***The Life Science Executive's Fundraising Manifesto*** reveals the expertise required to continually fundraise and bring your ideas to market.

FOR MORE INFORMATION

Visit www.FundraisingManifesto.com
or visit the Life Science Nation table in the exhibit hall

PARTNERING FORUM

Location: Essex Ballroom & Staffordshire

SEPTEMBER 17: IN-PERSON PARTNERING MEETINGS
SEPTEMBER 18-19: VIRTUAL PARTNERING MEETINGS

Investor/In-licensor Type	*Percentage*
Venture Capital	27%
Angel & Family Office	19%
Big Pharma & Medtech	17%
Corporate VC	14%
Others	8%
Endowments/Foundations	6%
Government Organizations	9%

Startup Type	*Percentage*
Therapeutics	47%
Medical Device	32%
Diagnostics	16%
Digital Health	5%

Service Provider Type	*Percentage*
Professional Services	39%
CRO/CMO	30%
Non-Profit	18%
Suppliers	8%
Others	5%

Who Meets with Whom at RESI Conferences



RESI provides a partnering forum for all stakeholders in the life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.

9:00 AM - 4:50 PM | INVESTOR PANELS

Location: *St. George A*

Moderator & Panelists	
9:00 - 9:50 AM **IMPACT INVESTORS & VENTURE PHILANTHROPY PANEL** *The Role of Impact Investing in the Healthcare Ecosystem*	**David Fogel,** Member of Screening & Due Diligence Committees, Mass Medical Angels **(Moderator)** **Jonathan Behr,** Partner, Dementia Discovery Fund **Andres Hurtado-Lorenzo,** Senior Vice President, Translational Research & IBD Ventures, Crohn's and Colitis Foundation **Ron Levin,** Managing Partner, Alumni Ventures **Markus Schreyer,** CEO, The Ganesha Lab **Stephanie Oestreich,** Managing Director, Myeloma Investment Fund
10:00 - 10:50 AM **MENTAL & BEHAVIORAL HEALTH PANEL** *Investing in Solutions for Higher Quality of Life and Wellbeing*	**Mahesh Narayanan,** Managing Partner, Neuvation Ventures **(Moderator)** **John Abeles,** General Partner, Northlea Partners **David Berry,** Managing Partner, Averin Capital **Jaja Liao,** Partner, 25madison Ventures **Arianne Kidder,** Partner, Seae Ventures **Nune Martiros,** Senior Associate, Paladin Capital Group
11:00 - 11:50 AM **ONCOLOGY INNOVATION PANEL** *Latest Scientific Breakthroughs and Future Outlook*	**Wei Tao,** Board Director & Chair, Bio/Genomics, Life Science Angels **(Moderator)** **Adam Cotton,** Principal, Novartis Venture Fund **Eric Furfine,** CEO & CSO, Mosaic Biosciences **Vivian Li,** Investor, K2 Venture Partners **Catherine Stace,** VP Business Development and Strategic Partnerships, o2h Ventures / o2h Discovery
1:00 - 1:50 PM **CORPORATE VC PANEL** *Venture and Innovation Arms Making Strategic Investments*	**Andrew Merken,** Shareholder, Polsinelli PC **(Moderator)** **Alex de Winter,** Vice President of New Ventures, Danaher Corporation **Claire Leurent,** Managing Director, AbbVie Ventures **Jeffrey Moore,** President, MP Healthcare Venture Management (MPH) **Komeil Nasrollahi,** Senior Director Innovation & Venture Partnerships, Siemens Healthineers
2:00 - 2:50 PM **DIAGNOSTICS PANEL** *Investing in Innovations for Preventative and Personalized Care*	**John Tremblay,** Investor, Launchpad Venture Group **(Moderator)** **Navin Govind,** Partner, Evidence Ventures **Anula Jayasuriya,** Co-Founder and Partner, Kidron Capital **Chris Murray,** Principal, MVM Life Science Partners **Mike Thomas,** Managing Partner, Bold Brain Capital **Chensu Wang,** Investment Manager, Yonjin Venture
3:00 - 3:50 PM **PARTNERING WITH BIG PHARMA PANEL** *What Startups Need to Know to Get on Big Pharma's Radar*	**Jeremy Sohn,** Managing Partner, P74 Ventures **(Moderator)** **Hyelim Cho,** Sr Director, BD and Alliance Management, RayzeBio (a Bristol Myers Squibb company) **Nikhil Mutyal,** Head of Search and Evaluation, Respiratory and Immunology, AstraZeneca **Armin Rump,** Director of Global Business Development, Otsuka Pharmaceutical Co., Ltd. **Ethan Than,** Global Digital/AI Strategic Partnerships & Transactions (BD&L), Sanofi **Jenny Wang,** Director, Search & Evaluation, Oncology, AbbVie
4:00 - 4:50 PM **FAMILY OFFICES PANEL** *Perspectives on Early-Stage Investments*	**John Pennett,** Angel Investor, Mid Atlantic Bio Angels **(Moderator)** **Marc Appel,** Managing Partner, Pacific Bridge NY **Yizhen Dong,** Managing Partner, Raise Health **Michael Loftus,** Director, PoC Capital **Renee Masi,** Senior Managing Director, KOFA Healthcare **Tyler Wanke,** Investor, Wanke Family Office

9:00 AM | IMPACT INVESTORS & VENTURE PHILANTHROPY PANEL

The Role of Impact Investing in the Healthcare Ecosystem

As the demand for meaningful innovation in healthcare grows, impact investors and venture philanthropists are stepping in to support early-stage life science and healthcare companies. These funders are driven not only by the potential for financial return, but also by the goal of advancing health equity, improving patient outcomes, and addressing critical unmet needs.

This 50-minute panel brings together leaders in impact investing and venture philanthropy to discuss how they deploy capital to catalyze innovation, particularly in areas often overlooked by traditional venture investors. Panelists will explore how they define and measure impact, what they look for in early-stage ventures, and how they work with founders to align mission with milestone-based growth. Hear from investors who are helping shape a more inclusive and outcomes-focused healthcare future.

David Fogel, Member of Screening & Due Diligence Committees, Mass Medical Angels **(Moderator)**

David Fogel is Managing Director of Swifton CFOs LLC, an outsourced CFO firm that provides emerging businesses with strategic and cost-effective financial leadership. David has been an active presenter and panelist with TechStars, MassChallenge, CleanTech Open, The Venture Forum, Greentown Labs, MIT Enterprise Forum Smart Start Program, M2D2 and YouthCities. He is also an active member of the screening and due diligence committees of Beacon Angels, TiE Boston Angels and Mass Medical Angels. David also is an Adjunct Instructor at Northeastern University and WPI.

Jonathan Behr, Partner, Dementia Discovery Fund

Jonathan Behr, Ph.D. is Managing Partner at SV Health Investors, where he co-leads the Dementia Discovery Fund (DDF) and serves on the Boards of several portfolio companies, including Montara, Nitrase, QurAlis, Ribometrix, Sudo, Transposon, and Violet Therapeutics. Previously, he was the first Managing Director of the T1D Fund, where he built its investment strategy and portfolio, leading to multiple high-profile acquisitions. Earlier in his career, he held leadership roles at Partners Healthcare Innovation, PureTech Ventures, and Enlight Biosciences. Dr. Behr earned his Ph.D. in Biological Engineering from MIT and his B.S. in Bioengineering from Rice University.

Andres Hurtado-Lorenzo, Senior Vice President, Translational Research & IBD Ventures, Crohn's and Colitis Foundation

Andres Hurtado-Lorenzo, Ph.D. is Senior Vice President of Translational Research & IBD Ventures at the Crohn's & Colitis Foundation. He oversees the Foundation's translational research portfolio in precision medicine, genetics, microbiome, fibrosis, pain, biosensors, and environmental triggers. He also launched and leads IBD Ventures, a venture philanthropy program that advances new IBD products by investing in for-profit and non-profit organizations. Previously, he directed drug discovery and development teams at Wyeth, Pfizer, and Proteostasis Therapeutics. Dr. Hurtado-Lorenzo earned his Ph.D. in Molecular Medicine & Gene Therapy from the University of Manchester and completed postdoctoral work at Harvard, MGH, and Columbia University.

Ron Levin, Managing Partner, Alumni Ventures

Ron Levin is Managing Partner and Head of the Seed Fund at Alumni Ventures, the world's leading venture capital firm for individual investors. He has built his career across entrepreneurship, strategy, and business development, co-founding and serving as CEO of TravelPerk, a VC-backed travel management platform that achieved unicorn status. Earlier, Ron launched the B2B division of Booking.com and worked as a management consultant with McKinsey & Co., after starting his career at Lycos. A graduate of Babson College with an MBA from Harvard Business School, Ron has lived in four European cities and traveled to 140+ countries. He is also the author of Higher Purpose Venture Capital and writes the bi-weekly Higher Purpose SmörgåsBlog.

Markus Schreyer, CEO, The Ganesha Lab

Markus is a German executive and entrepreneur with 30+ years of international experience across Europe, the USA, Brazil, Asia, and now Latin America. He is the Founder of The Ganesha Lab, a global biotech scale-up that supports Latin American startups through internationalization, scale-up, and funding. Backed by a team of experts and industry partners, he has guided 30+ early-stage companies, launching several from LatAm to the U.S., and recently established The Ganesha Lab Fund I to expand impact and investor returns. Previously, Markus held leadership roles at Thermo Fisher Scientific and Fisons Instruments, driving growth through product innovation and strategic transitions. He is also a member of Chile Global Angels, where he served on the board from 2016 to 2020.

Stephanie Oestreich, Managing Director, Myeloma Investment Fund

Stephanie Oestreich is Managing Director of the Myeloma Investment Fund (MIF) and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of SpringBoard Ventures, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx and to the drug development and investment company OrangeGrove Bio Previously she was Chief Business Officer at Galecto, Vice President at cell therapy company Mnemo Therapeutics, a Venture Partner at RA Capital and Executive Vice President at Evotec where she built its North American investment arm and started an incubator with Samsara BioCapital. She also worked as International Business Leader at F. Roche Hoffmann-La Roche Ltd., and for Novartis in Business Development and in Commercial. Stephanie conducted the research for her Ph.D. in biochemistry in the lab of a Nobel Prize winner at Harvard Medical School and obtained an MPA from the Harvard Kennedy School

10:00 AM | MENTAL & BEHAVIORAL HEALTH PANEL

Investing in Solutions for Higher Quality of Life and Wellbeing

In 2022, WHO announced in their factsheet that 1 in every 8 people in the world live with a mental disorder. With ongoing efforts to raise awareness and reduce stigma, there continues to be a high demand for new solutions and investors are taking notice. From digital therapeutics and neurotechnology to novel therapeutics and care delivery models, early-stage companies are pushing the boundaries of how mental and behavioral health can be diagnosed, treated, and managed. This 50-minute panel will feature investors actively backing innovation in mental and behavioral health. Panelists will discuss where they see the most promising opportunities, how they evaluate clinical and commercial potential in a complex and often fragmented market, and what it takes for early-stage companies to stand out. The conversation will also explore how stigma, reimbursement challenges, and regulatory pathways impact investment decisions—and how emerging technologies and models of care are reshaping the landscape.

For companies developing tools for anxiety, depression, addiction, neurodevelopmental disorders, or serious mental illness, or for investors who are looking more into investing in mental and behavioral health-related disorders, this session will offer practical insights into how investors are supporting the next generation of mental health solutions.

Mahesh Narayanan, Managing Partner, Neuvation Ventures **(Moderator)**

Mahesh Narayanan is a founder, investor, and accelerator director with deep expertise in business development and startup strategy. He serves as Managing Partner at Neuvation Ventures, a Baltimore-based seed fund backing U.S. companies driving deep tech innovation in brain health. With a background in neuroscience and oncology, he previously taught anatomy and physiology in Philadelphia. Over 15+ years, Mahesh has led life science startups from pre-revenue to licensing deals exceeding $50M, giving him unique insight into guiding early-stage ventures toward sustainable growth. He holds a Master's in Biotechnology from the University of Pennsylvania and dual bachelor's degrees in history and neuroscience from Boston University, combining scientific expertise with entrepreneurial leadership.

John Abeles, General Partner, Northlea Partners

Dr. John H. Abeles, BSc (Hons), MBChB is a physician, pharmacologist, and investor with over four decades of experience in biomedicine and venture capital. After practicing medicine in London and Connecticut, he held senior medical roles at Sterling Drug, Pfizer, and USV. In 1975, he became the first full-time physician-analyst on Wall Street with Kidder Peabody. He later founded MedVest Group, a biomedical consulting entity, and Northlea Partners, his family office with an active venture capital practice. Dr. Abeles has advised UC Berkeley, Stanford, and Kansas, and serves on multiple healthcare and nonprofit boards in the US and Israel.

David Berry, Managing Partner, Averin Capital

As a career innovator, entrepreneur, and investor, David co-founded Averin with the vision of bringing forth a new era in health–one powered by technology and that can lead to better outcomes for patients everywhere, faster, and at lower cost. Prior to Averin, David co-founded over 30 companies across life sciences and sustainability, including 7 that were valued over $1B. He was previously a General Partner at Flagship Pioneering. David has been broadly recognized as a world-leading innovator, having been elected as a Young Global Leader by the World Economic Forum, named an Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected by the U.S. State Department as one of 12 Innovators Reshaping Reality alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications. David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering. He received a B.S. from MIT in Brain and Cognitive Sciences.

Jaja Liao, Partner, 25madison Ventures

Jaja Liao is a Partner at 25madison Ventures, where she invests in early-stage companies and partners with founders to scale bold ideas into impactful businesses. She looks for visionary entrepreneurs who build products that inspire customer obsession. Jaja studied Molecular Biology at Yale University, but found her passion at the intersection of technology and venture. She previously invested in healthcare, consumer, and SaaS companies at Headline (formerly e.ventures) in San Francisco. Her career began at Google in the Online Partnerships Group, followed by roles in Growth Strategy & Operations at Clover Health, Business Development at TikTok—as one of its first U.S. employees—and early-stage investing at Rainfall Ventures.

Arianne Kidder, Partner, Seae Ventures

Arianne Kidder is a Partner at Seae Ventures with 19 years of finance and operations leadership across healthcare and technology, spanning early-stage startups to Fortune 500 companies. She previously held finance roles at digital health companies, where she raised $70M in capital and managed a successful company sale. Earlier in her career, Arianne spent 11 years at Ernst & Young in the Boston Financial Services practice, building expertise in payors, healthcare, governance, and finance. A graduate of Boston University's Questrom School of Business, she also volunteers with Invest in Girls, the Boys & Girls Club, and her local schools.

Nune Martiros, Senior Associate, Paladin Capital Group

Dr. Nuné Martiros works on sourcing and assessing investments for the Digital Biology fund at Paladin Capital, including interfacing with Paladin-founded venture studio General Inception. She previously worked on developing and assessing early stage biotechnology companies at Foresite Labs and was a Fellow at Flagship Pioneering. Nuné completed her undergraduate studies and doctoral thesis research in neuroscience at MIT and postdoctoral research at Harvard University. Her research focused on using electrophysiology and multiphoton imaging to study the real-time activity of basal ganglia neuronal populations, the role of dopamine signaling, and olfactory sensory input. Dr. Martiros is the lead author on multiple research publications in scientific journals and has been the recipient of multiple research grants from the NIH. She has a particular focus on sourcing investments from the active Boston biotechnology innovation ecosystem.

11:00 AM | ONCOLOGY INNOVATION PANEL

Latest Scientific Breakthroughs and Future Outlook

Oncology remains one of the most dynamic and competitive areas in life science innovation, attracting sustained investor interest and driving scientific breakthroughs across diagnostics, therapeutics, and digital platforms. However, many challenges are afoot – with increasing scientific complexity, regulatory demands, and rising development costs, early-stage oncology companies must demonstrate not only novel science, but real potential for clinical and commercial impact.

This 50-minute panel will bring together active investors and strategic partners focused on oncology innovation. Panelists will explore which technologies and modalities are capturing attention as well as future outlook on how this field will continue to evolve. The discussion will also cover what makes an oncology startup stand out in a crowded field, how investors assess differentiation and de-risking at early stages, and where the biggest unmet needs remain.

For any company that is addressing oncology – from novel therapeutics to preventative diagnostics – this session will offer valuable insights into partnering and funding strategies at the cutting edge of cancer care.

Wei Tao, Board Director & Chair, Bio/Genomics, Life Science Angels **(Moderator)**

Wei Tao, Ph.D., is a Silicon Valley based investor passionate about venture investment. Dr Tao focuses on early stage life science and healthcare companies with explosive growth potential, commercializing disruptive technology to address critical unmet needs and improve societal well being. Dr. Tao is a sought-after value-add investor and adviser. He built extensive connections with the entrepreneurial community in Silicon Valley and beyond. Dr. Tao is an adviser to a number of entrepreneurship initiatives at leading institutions such as Stanford University, UC Berkeley and UCSF. As a result he enjoys unparalleled access to proprietary deal flow, screening hundreds of promising deals every year. He is an active member of Life Science Angels, the premier life science focused investment group. He served on the board of LSA and several venture-backed companies.

Adam Cotton, Principal, Novartis Venture Fund

Adam Cotton PhD, MBA is a Principal at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he worked in the labs of Jim Wells and Ian Seiple on antibody engineering research. He is a scientific co-founder of Epi Biologics. He helped build both Rezo Therapeutics and HYKU Biosciences as they transitioned from their respective academic labs. He holds a BA in Chemistry from Harvard University, an MBA from the University of New Mexico, and a PhD in Chemistry & Chemical Biology from the University of California, San Francisco.

Eric Furfine, CEO & CSO, Mosaic Biosciences

Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Executive and Scientific Office at Mosaic. He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President of R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal on a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisition of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development at Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea. Eric received his PhD in Biochemistry from Brandeis University

Vivian Li, Investor, K2 Venture Partners

Vivian Li, PhD, MBA is an Investor at K2 Venture Partners with expertise spanning biomedical research, drug discovery, and early-stage investment. She began her career as a Postdoctoral Researcher and Staff Scientist at Penn Medicine, focusing on biomarker development and IND-enabling studies, before transitioning to discovery research at GSK. Following her MBA, Vivian pivoted into venture capital, where she combines deep scientific knowledge with strategic and deal-making skills to evaluate and nurture transformative biotech innovations. Passionate about advancing cutting-edge science into commercial success, she partners with founders to accelerate healthcare breakthroughs from concept to market.

Catherine Stace, VP Business Development and Strategic Partnerships, o2h Ventures / o2h Discovery

Catherine has 20 years experience in the Biotech industry, specialising in developing platform technologies and commercialisation. She has held strategic technology and business development roles, covering small molecule therapeutics, peptides, drug conjugates, nanoparticles, HealthTech and engineering. Currently VP at o2h – a UK company comprising Ventures, Discovery services, and an Incubator – Catherine supports many innovative life sciences companies as they strive to meet scientific milestones for partnerships and investment. Catherine is also EVP BD at Kuano, an o2h Ventures portfolio company specialising in quantum-based in silico drug design, with a pipeline of early-stage cancer therapeutics. Catherine has hands-on experience and leadership of over 30 early-stage discovery projects, many for oncology, and including two peptides in the clinic for Bicycle Therapeutics. As technology consultant to start-ups, Catherine then worked across multiple modalities, before moving to Exec level commercial roles in the small molecule field. Catherine holds an MSci Chemistry, PhD Cell Biology from Cambridge, MBA specialising in innovation commercialisation, and is inventor on 17 patents for technologies and therapeutics.

1:00 PM | CORPORATE VC PANEL

Venture and Innovation Arms Making Strategic Investments

Many large corporations establish corporate venture or innovation arms to invest and partner with life science and healthcare companies. However, every corporate venture capital firm has a unique approach and strategy in investment, and their ties to the corporation can differ. Some invest only in areas that complement the parent company's existing interest areas, while some may source for opportunities beyond those interest areas.

This 50-minute panel will feature leaders from the corporate venture arms of global pharma, biotech, and medtech companies, and other major corporations in the healthcare industry. Panelists will discuss how they identify and evaluate early-stage opportunities, how their investment criteria differ from institutional VCs, and how they balance strategic alignment with return potential. The conversation will also cover how startups can navigate relationships with CVCs, what they can expect beyond capital, how collaboration may evolve post-investment, and how to position themselves for success with strategic partners.

For anyone who is seeking investment from a CVC, this panel will uncover insights from active corporate VC firms and how they seek to drive innovation, accelerate R&D, and bring transformative solutions to market.

Andrew Merken, Shareholder, Polsinelli PC **(Moderator)**

Andrew Merken is a nationally recognized corporate and transactional lawyer advising early to growth-stage companies across the full business lifecycle, from formation to funding, M&A, and IPO. He provides strategic counsel and works closely with subject matter experts in FDA, IP, employment, tax, and cross-border matters. Andy also represents VC funds, angel investors, family offices, and foundations in investments and collaborations, as well as investment banks in public and private offerings. His clients span life sciences, including biotech, pharma, medtech, and digital health, as well as high-tech sectors such as consulting, real estate, and food services. Andy is known for guiding companies through complex deals and delivering practical, business-oriented legal advice.

Alex de Winter, Vice President of New Ventures, Danaher Corporation

Alex de Winter is with Danaher Equity Ventures, where he invests in life sciences tools and clinical diagnostic startups. Prior to Danaher, he was a managing director at GE Ventures, where he invested in precision medicine startups like Labcyte, Raindance, Singular Genomics, Syapse, and Veracyte. Alex previously worked at Mohr Davidow Ventures, and was a research scientist at Pacific Biosciences and 454 Life Sciences. Alex earned his PhD in Chemistry from Stanford, his MBA from UC Berkeley, and his BA in Chemistry and English from Amherst College.

Claire Leurent, Managing Director, AbbVie Ventures

Claire, PhD, MBA is a molecular and cellular biologist with extensive experience leading preclinical and clinical drug development programs. She combines 14 years of research and development expertise at Forenap Pharma, Wyeth Pharmaceuticals, and Pfizer with a strong track record in venture capital, spanning all investment stages from seed to IPO, PIPE, and SPAC. Claire has held investment roles at Samsung Venture America and Johnson & Johnson Development Corporation, and most recently served as Entrepreneur in Residence at the NIH. She earned her PhD in Genetics, Molecular and Cellular Biology in Strasbourg, France, and her MBA from MIT Sloan.

Jeffrey Moore, President, MP Healthcare Venture Management (MPH)

Jeff Moore is President of MP Healthcare Venture Management (MPH), the VC firm of Mitsubishi Tanabe Pharma Corporation. MPH is a Boston-based lifesciences venture capital firm investing in companies developing innovative therapeutics, platform technologies and vaccines. Dr. Moore led MPH's investments in GlycoEra, Trimtech, F-Star, Covagen, Forge, Blacksmith, Genocea, Korro, QurAlis, Thrasos, Ribometrix, miRagen, Outrun, and PharmEnable. Previously, Dr. Moore was a Kauffman Fellow with the early stage venture firm Research Corporation Technologies. He has held various business and scientific roles at Millennium Pharmaceuticals and Scriptgen Therapeutics. He received his DPhil from the University of Oxford, studying virus vaccines, and then did postdoctoral training in infectious disease at Harvard Medical School. Dr. Moore received his MBA as a Sloan Fellow at MIT, and his BSc in Biology from the University of New Brunswick.

Komeil Nasrollahi, Senior Director Innovation & Venture Partnerships, Siemens Healthineers

Komeil Nasrollahi is a senior director of innovation and venture partnerships at Siemens Healthineers, one of the world's largest medical device companies. He leads global initiatives to identify, evaluate, and scale emerging technologies in collaboration with startups, VC firms, and healthcare systems. With experience founding two companies and building strategic partnerships across the U.S., Asia, and Europe, Komeil brings a unique ability to bridge startup innovation with enterprise scale. He also serves as an adjunct MBA faculty member at West Chester University, teaching entrepreneurship and venture creation since 2018. Komeil is passionate about supporting early stage founders, particularly in healthcare, AI, and enterprise solutions by helping them navigate commercialization, corporate partnerships, and go-to-market strategy within the U.S. healthcare system.

2:00 PM | DIAGNOSTICS PANEL

Investing in Innovations for Preventative and Personalized Care

Diagnostics are playing an increasingly central role in the future of healthcare by enabling earlier detection, more precise treatment, and better patient outcomes. From next-generation sequencing and liquid biopsy to digital and AI-powered tools, diagnostics are transforming how we understand and manage disease, ultimately leading to better patient outcomes.

This 50-minute panel will feature investors and strategic partners focused on early-stage diagnostics innovation. Panelists will explore what makes a diagnostic technology attractive from both a clinical and commercial standpoint, how they evaluate reimbursement potential and regulatory pathways, and where they see the biggest unmet needs. The discussion will also highlight how diagnostics companies can differentiate themselves, gain early traction, and successfully partner with investors or industry leaders.

For fundraising entrepreneurs developing novel solutions in oncology, infectious disease, chronic conditions, or personalized medicine, this session will offer practical insights on funding, positioning, and scaling impactful diagnostic solutions and how your company can stand out to active investors and strategic partners.

John Tremblay, Investor, Launchpad Venture Group **(Moderator)**

John is an angel investor with LaunchPad Venture Group and leads the digital health innovation consulting practice at Healthy Context, LLC. He helps organizations operationalize high impact healthcare transformations and new capabilities that become industry benchmarks for care delivery. Recently, he was Vice President of Digital Strategy & Portfolio for the $5B MedTech renal care business at Fresenius Medical Care. He helped launch 2 successful life-saving home therapies now serving 34k+ patients in the US with world-class rated clinician experiences. John was an NSF I-CORPS instructor and co-program lead of a university lean innovation incubator to confirm product-market fit for deep technology spinouts. John has both a technology innovation MBA and a BS in electrical engineering from Northeastern University.

Navin Govind, Partner, Evidence Ventures

Navin Govind is a serial entrepreneur, investor, and venture partner at Evidence Ventures. He is the Founder & CEO of Aventyn, a digital therapeutics company delivering clinically validated platforms to improve cardio-kidney-metabolic health. With deep expertise at the intersection of technology, medical devices, and digital health, Navin has authored peer-reviewed papers, holds multiple patents, and advises startups and global clients. He also co-founded K-Labs, driving advanced AI-enabled health data collaborations to reduce chronic disease burden and healthcare costs. Navin serves on advisory boards including the American Heart Association's Center for Health Technology & Innovation and WearTech Applied Research Center.

Anula Jayasuriya, Co-Founder and Partner, Kidron Capital

Founding Managing Partner of four investment funds: EXXclaim Capital, Evolvence India Life Science Fund I and II, and Kidron Capital. Exited three Women's Health Investments. Co-founder of Artemis Women's Health Foundation, and Vice Chair of WHAM. Former Vice President at Roche Pharmaceuticals. Board member of several private Women's Health companies, and two publicly listed entities.

Chris Murray, Principal, MVM Life Science Partners

Chris joined MVM in 2024. Prior to MVM, he was a manager at Bain & Company where he advised payor, provider, and healthcare IT clients on strategy and diligenced a broad range of healthcare assets for private equity firms. Before consulting, Chris trained in emergency medicine at Mass General Brigham. He received his MD from Harvard Medical School and MBA from Harvard Business School. Chris also holds a BA magna cum laude in global affairs from Yale.

Mike Thomas, Managing Partner, Bold Brain Capital

Mike is Managing Partner at Bold Brain Capital, an AI-focused venture capital firm investing in digital health startups in imaging. He also serves as a fractional CEO for medtech and digital health startups, and as Senior Commercialization Advisor at the NobleReach Foundation, supporting spinouts from leading universities, NSF, and DARPA's Embedded Entrepreneur Initiative. Previously, Mike helped architect ARPA-H as part of the White House OSTP, led commercialization strategy, and managed a $150M fund at Inova Health System. A serial CEO for 25+ years, he has raised $125M, led an IPO, two acquisitions, and delivered 4x–80x shareholder returns.

Chensu Wang, Investment Manager, Yonjin Venture

Chensu is an Investment Manager at Yonjin Venture, specializing in innovative therapies and medical devices. Previously, she was a Consultant at Boston Consulting Group (BCG), advising global biopharma and medtech firms. Before joining BCG, she served as a Senior Scientist at Pfizer, focusing on immuno-oncology drug discovery. Chensu holds a PhD in Biomedical Engineering from UT Southwestern Medical Center, with postdoctoral training in immuno-oncology at Massachusetts Institute of Technology, and a BS in Biomedical Engineering from Southeast University, China.

3:00 PM | PARTNERING WITH BIG PHARMA PANEL

What Startups Need to Know to Get on Big Pharma's Radar

For many early-stage life science companies, partnering with Big Pharma is a critical milestone, as these major pharmaceutical companies offer access to global expertise, resources, and commercialization pathways. But competition is fierce, and successful partnerships require more than great science. They demand clear differentiation, strong data, strategic alignment, and a compelling case for unmet need.

This 50-minute panel will feature business development and venture leaders from major pharmaceutical companies who are actively scouting for innovation across therapeutics, diagnostics, digital health, and enabling technologies. Panelists will share what they look for in early-stage companies, how their teams evaluate external opportunities, and when in the development cycle they are willing to engage. The discussion will also explore trends shaping pharma's innovation strategy and how startups can position themselves for long-term, high-impact partnerships.

Whether you are aiming for a co-development deal, licensing agreement, or strategic investment, this session offers an inside look at how big pharm thinks, and what it takes to stand out.

Jeremy Sohn, Managing Partner, P74 Ventures **(Moderator)**

Jeremy is a venture investor, entrepreneur, and life sciences leader with 25 years of experience driving business model transformation. He is Managing Partner at P74 Ventures, a fund focused on platform technologies. Since 2013, he has completed 26 investments, led partnerships with over 100 start-ups and tech leaders, and developed eight transformational platforms. Previously, he was VP and Global Head of Digital BD&L at Novartis, overseeing digital health ventures, partnerships, and the Novartis Biome. Before that, he was Managing Director at MPM Capital, leading its pharma-tech fund. Earlier in his career, he co-founded Wasabi Systems, an open-source OS company, serving as CFO and VP of Business Development.

Hyelim Cho, Sr Director, BD and Alliance Management, RayzeBio (a Bristol Myers Squibb company)

Hyelim Cho is a seasoned business development leader with a diverse background spanning R&D, portfolio management, and strategic partnerships. She brings a multidisciplinary approach to innovation and organizational growth, known for breaking down silos, fostering cross-functional collaboration, and aligning scientific and business priorities. As Senior Director of Business Development and Alliance Management at Bristol Myers Squibb (RayzeBio), Hyelim leads initiatives in oncology and radiopharmaceuticals, driving innovative partnerships and portfolio strategies. Her experience covers the full spectrum from discovery and development to BD&L and research operations, with a proven track record of navigating complex priorities and accelerating growth.

Nikhil Mutyal, Head of Search and Evaluation, Respiratory and Immunology, AstraZeneca

Nikhil is currently Head of Search and Evaluation for Respiratory and Immunology (R&I) at AstraZeneca in this role he is responsible for deal making in R&I across all stages, geographies, and modalities. Previously, Nikhil was Executive Director in BD&L at Merck and Co (MSD) and Head of Oncology BD at Jazz Pharmaceuticals. Nikhil has Ph.D. In Biomedical Engineering from Northwestern University.

Armin Rump, Director of Global Business Development, Otsuka Pharmaceutical Co., Ltd.

Armin Rump has extensive experience in all aspects of business development, from scouting and evaluation to due diligence, deal negotiation and closure, across therapeutics, diagnostics and digital health. After five years at Otsuka's head office in Japan, Armin moved to Otsuka's US office in 2016, where he is currently responsible for scouting, search and evaluation, with a focus on Otsuka's global therapeutic areas of interest, psychiatry, neurology, nephrology and autoimmune diseases. He obtained a Ph.D. degree in Molecular Cell Biology from the University of Tokyo and a master's degree in Biotechnology from the University of Stuttgart. Armin is passionate about great science and novel approaches to address serious unmet needs for patients worldwide, particularly in chronic diseases, where large clinical studies can be required, draining the resources of any single company.

Ethan Than, Global Digital/AI Strategic Partnerships & Transactions (BD&L), Sanofi

Ethan Than leads Global AI/Digital BD&L at Sanofi, where he forges transformative collaborations across the healthcare ecosystem. A seasoned executive with extensive experience in digital health and biopharma, he has led R&D and commercial-stage deals—structuring strategic partnerships, research collaborations, and licensing agreements that accelerate innovation. His career spans the full spectrum of drug development, from discovery to product commercialization. Earlier in his career, Ethan spent time at Pfizer and early-stage biotech in leadership roles, building and leading teams developing key therapeutic programs and launching commercial drug assets. As a former startup founder and active mentor in the startup ecosystem, he continues to support early-stage companies with strategic guidance. Ethan is passionate about advancing healthier aging through impactful, tech-enabled solutions.



Jenny Wang, Director, Search & Evaluation, Oncology, AbbVie

Jenny Wang is Director of Search & Evaluation, Oncology at AbbVie and a results-driven leader with deep expertise in global learning and development, operations, and performance optimization. She has designed and implemented large-scale training programs, curriculum strategies, and effectiveness evaluations that strengthen organizational capability and drive measurable outcomes. Jenny is highly skilled in project management, process improvement, change management, and leveraging learning management systems (LMS) to scale impact. Known as a forward-thinking leader, she empowers organizations to achieve growth and operational excellence through sustainable, proactive learning and development strategies aligned with business objectives.

4:00 PM | FAMILY OFFICES PANEL

Perspectives on Early-Stage Investments

Family offices are becoming increasingly active players in early-stage healthcare and life science investing and have growing interest in high-impact innovation. They are on the radar of many early-stage companies as they provide patient capital, diverse investment strategies. Unlike traditional venture funds, family offices may prioritize mission alignment, multi-generational value creation, and cross-sector impact alongside financial returns.

This 50-minute panel features family office investors with a strong focus on healthcare and life sciences. Panelists will share what drives their interest in the sector, how they evaluate opportunities, and what sets them apart from institutional VCs. The discussion will also explore how founders can engage with family offices, what makes a company stand out, and how these investors support portfolio companies beyond capital.

The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching, and working with these groups as well as debunking some common misconceptions about family offices.

John Pennett, Angel Investor, Mid Atlantic Bio Angels **(Moderator)**

John Pennett is Partner-in-Charge of the National Technology and Life Sciences Group at Eisner Advisory Group LLC and a member of Mid-Atlantic Bio Angels, an angel group focused on emerging life sciences companies. With 35 years of public accounting experience, he has led over 50 IPOs, private financings, and M&A deals totaling $3B+. John also contributes to EisnerAmper's Catalyst newsletter and regularly writes and speaks on industry topics. He supports entrepreneurial organizations nationwide and mentors early-stage startups. His expertise spans auditing, risk advisory, Sarbanes-Oxley compliance, outsourced accounting, and international services. Previously, he was an Audit Partner at an international consulting firm.

Marc Appel, Managing Partner, Pacific Bridge NY

Marc Appel, JD, MBA, is an advisor to university innovation programs including Yale's Blavatnik Program, Cornell's tech transfer office, and Dartmouth's Cancer Accelerator. He founded Orange Grove Bio and served as its CEO from 2019 to 2024, also helping launch biotech companies like IpiNovyx Bio and Allonix Therapeutics. Marc was previously a healthcare investor at Marathon Asset Management, Highbridge Principal Strategies, and Eaton Vance, and began his career at McKinsey & Co. He frequently speaks at industry conferences and universities and co-authored a Harvard Business School case on Imprimis Pharmaceuticals. He holds a B.A. from Yale, a J.D. from Harvard Law School, and an M.B.A. from Harvard Business School. He is a member of the New York Bar.

Yizhen Dong, Managing Partner, Raise Health

Raise Health is an extension of family offices that directly invest in life sciences, spanning from life sciences tech/services to therapeutics at the early stage. We accelerate biotechs to human proof of concept through capital investment and proprietary clinical infrastructure. Previously, Yizhen was a Partner at Global Founders Capital where he led early stage investments in the frontier of bio, including AI in healthcare innovations, computational biology, synthetic biology, neurotech, medical robotics, and life sciences software. Prior to GFC, Yizhen was a Principal at 11.2 Capital where he led investments in computational biology and synthetic biology. Prior to 11.2 Capital, Yizhen helped launch Avastin in two cancer indications and developed marketing strategies across the product portfolio at Roche/Genentech. Yizhen was formerly a management consultant at ZS Associates after being a trained sushi chef for 7 years. Yizhen graduated magna cum laude in Economics from Vanderbilt University and received his MBA from The University of Chicago Booth School of Business.

Michael Loftus, Director, PoC Capital

Michael Loftus, Director at PoC Capital, is a highly connected and accomplished executive in biotech financing and clinical trials. Renowned for his strategic vision, extensive industry network, and proven ability to execute complex transactions, Michael is a trusted partner for early- to mid-stage biotech companies seeking capital-efficient solutions for clinical trials. At PoC Capital, Michael leads efforts to fund public microcap biotechs listed on NASDAQ or NYSE, with market capitalizations ranging from $10 million to $200 million. The firm specializes in supporting Phase Ib, IIa, or similarly sized clinical trials, with average deal sizes between $2 million and $6 million.

Renee Masi, Senior Managing Director, KOFA Healthcare

Renee Masi is Senior Managing Director at KOFA Healthcare, LLC, the venture arm of a single-member family office backed by a multibillion-dollar Chinese conglomerate. She joined KOFA to formalize its venture efforts, with a strong focus on cardiovascular innovation, and has recently led investments in Aria CV, Venova Medical, and CorFlow. Previously, Renee spent 18 years at BioStar Capital, a physician-led fund specializing in orthopedic and cardiovascular opportunities, where she also served on the boards of Foldax, Aria CV, Autonomix, and Ablative Solutions. Earlier in her career, she opened an East Coast office for a $200M venture fund and managed the healthcare portfolio of an early-stage fund in Southern California. Renee holds an MBA from Wharton and an AB from Stanford University.

Tyler Wanke, Investor, Wanke Family Office

Tyler Wanke, MD/MBA/MEM is a MedTech entrepreneur, investor, and professor. He co-founded Madison Scientific, Innoblative, and EDGe Surgical. He invests as an angel and on behalf of his family office. He is also a professor of medical entrepreneurship at Northwestern University.

9:00 AM - 4:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 1

Location: St. George B

Pitch Company				
9:00 - 9:50 AM SESSION #1 THERAPEUTICS	adipo THERAPEUTICS *Table #45*	Ignota Labs *Table #36*	Kare *Table #23*	PERSISTABIO *Table #26*
10:00 - 10:50 AM SESSION #2 THERAPEUTICS	MKP THERAPEUTICS *Table #20*	ONCOVITA *Table #46*	ReEngage Therapeutics *Table #17*	TroGen THERAPEUTICS *Table #38*
11:00 - 11:50 AM SESSION #3 MEDICAL DEVICE	alleviate *Table #47*	EXOSYSTEMS *Table #1*	TISSUE FORM *Table #7*	
1:00 - 1:50 PM SESSION #4 THERAPEUTICS	Bio Therapeutics *Table #35*	KORTUC *Table #5*	Numiera Therapeutics *Table #44*	TRBO TR Beta Oncology *Table #48*
2:00 - 2:50 PM SESSION #5 R&D AND ENABLING TECHNOLOGIES	ORGANOPlus *Table #15*	RadaHaim *Table #13*	RONAWK *Table #19*	THRIVE BIOSCIENCE *Table #25*
3:00 - 3:50 PM SESSION #6 THERAPEUTICS	BE Therapeutics *Table #16*	CURLIM *Table #3*	SENSA NEUROSCIENCE *Table #10*	Treasure biosciences *Table #18*
4:00 - 4:50 PM SESSION #7 THERAPEUTICS	BILIX *Table #14*	Elastrin The Only Therapy Proven to Reverse Arterial Calcification *Table #4*	inomagen *Table #30*	pacDNA Tx *Table #37*

9:00 AM | SESSION 1 - THERAPEUTICS

Adipo Therapeutics was founded to advance the treatment of obesity by increasing energy expenditure and promoting healthy weight loss. Adipo's lead asset provides a bold new approach to obesity treatment by creating healthier, energy burning subcutaneous fat to provide increased resting metabolic rate, weight loss, glucose control, and muscle preservation with no change in caloric intake. Adipo's technology uses Notch-inhibiting nanoparticles to convert energy-storing white fat to energy-burning brown fat. The treatment is being developed to be used alone or in combination with current anti-obesity medicines which are expected to have a market potential of $100+B annually by 2030. Adipo's executive team is highly experienced in drug development and manufacturing scale up. We have raised over $10M and are currently raising Series A funding closing on ~50% of a $15M target to advance the asset to Phase 1 human clinical studies.

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients. More than half of all clinical trials fail due to safety issues, resulting in a staggering $400 billion annual loss and delaying life-saving treatments for patients. Our proprietary platform, SAFEPATH, uses cutting-edge deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Unlike traditional safety assessments that identify what went wrong, our AI platform SAFEPATH combines cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues occur, delivering actionable insights to refine or repurpose drug candidates. Ignota Labs is building a robust pipeline to bring safer drugs to market faster, partnering to develop and co-develop assets that might otherwise fail, and accelerating the delivery of vital therapies to patients in need.

Kare Chemical Technologies Inc., is a pharmaceutical research and technology company which is currently using proprietary synthetic technology to develop novel medicines towards indications like chronic pain, without psychoactivity or addiction, to provide a solution to the opioid crisis. Kare is also developing novel medicines in the obesity and diabetic space through alternative pathways to GLP1. Previously Kare has also developed a novel and proprietary method of making children's medicines for indications like Epilepsy from industrial by-products. We have licensed this technology to pharmaceutical manufacturers who are producing pharmaceutical API and products.

Persista Bio's O2Line(TM) technology breaks through prior cell therapy roadblocks and enables implantable cell therapies—it avoids rejection and supports the long-term health of the cells. Recently published oreclinical data has already shown success in Type 1 Diabetes. Persista Bio's O2Line™ system includes: 1) a unique anti-fibrotic cell capsule which prevents immune rejection of the device and enables quick diffusion of the therapeutic, and 2) an in-situ oxygen generator to support the densely packed, macroencapsulated cells. This system will replace conventional therapies (injections, pumps, finger sticks) and enable advanced stem cell therapies without requiring immunosuppression. The O2Line implant system will be extended to additional indications. Persista Bio is a pre-clinical stage company with licensed technology from Cornell University and Giner, Inc. founded by Linda Tempelman, PhD; James Flanders, DVM;and Minglin Ma, PhD. Persista Bio is raising a seed round to accelerate its large animal proof of concept and full product design.

10:00 AM | SESSION 2 - THERAPEUTICS

M6P Therapeutics focuses on lysosomes (the natural recycling center for cells) and has the only technology that can deliver any protein to lysosomes – a feat deemed impossible for over 50 years. The company has a deep pipeline, 6 rare pediatric drug designations, and an IP portfolio comprised of 9 patent families, 8 issued patents, and 20 in progress. Our Gaucher Disease ERT is ready for the clinic and our Pompe Disease ERT – which can restore and normalize muscle function – will be ready in 18 months. We also created a platform that can take any antigen-antibody complex to the lysosomes of any cell in the body (instead of relying on Fc clearance by select immune cells) for degradation. Our "chimeric" anti-PD-L1 antibody removes virtually all PD-L1 from the surface of tumor cells while our chimeric version of Keytruda is twice as potent.

Founded in 2015 as a spin-off from the Institut Pasteur in Paris, Oncovita is a cutting-edge biotech company focused on developing life-saving immunovirotherapy treatments for cancer. At the heart of Oncovita's innovation is Measovir®, a proprietary platform built on a genetically modified measles virus vaccine. Leveraging its success in advanced clinical vaccine trials, the company is now concentrating on MVdeltaC, a promising candidate selected for its strong immunogenic and oncolytic activity. MVdeltaC has demonstrated high efficacy in vitro and in vivo, including in patient-derived xenograft (PDX) and immunocompetent syngeneic models. The company is preparing for GMP production, with plans to initiate a First-in-Human Phase I trial in 2026, followed by a Phase IIa study targeting Malignant Pleural Mesothelioma and Triple-Negative Breast Cancer.

ReEngage Therapeutics is a biopharmaceutical R&D company focused on developing therapeutics that treat longevity-related diseases. ReEngage does this by modifying epigenetic targets that are implicated in aging-related disorders, including neurodegeneration and cancer. We have developed novel small molecule inhibitors to a metabolic target, acetyl co-A synthetase (ACSS2), which is known to fuel epigenetic gene regulation. We have shown that our molecule MTB-9655 is safe and tolerable in humans, and now have elucidated its mechanism of action - downregulating expression of DNA damage repair genes, which contribute to chemo resistance. Further, MTB-9655 plus chemo in colorectal cancer (CRC) patient-derived xenograft models was shown to extend median survival by 50% over chemo-alone. We plan to initiate a phase 1b/2a study for third line metastatic colorectal cancer in 2026, led by PI Dr. Scott Kopetz of MD Anderson.

TroGen Therapeutics is building a next-generation gene therapy platform to overcome the major bottlenecks of cancer immunotherapy: lack of ideal tumor antigens, immunosuppressive tumor microenvironments, and systemic toxicity. Our Trojan Horse gene circuits act as smart decision-making units inside cancer cells, integrating proprietary tumor-specific promoters with programmable immune outputs. This enables precise recognition of tumor cells while sparing normal tissue, and the local release of potent therapeutic proteins (e.g., IL-12, CCL21, checkpoint inhibitors). Our platform, powered by high-throughput screening and AI optimization, achieves unmatched in vivo specificity and efficacy, even at partial delivery levels, and has outperformed gold-standard melanoma therapies in preclinical models. With broad modularity, our circuits can be adapted to diverse indications, positioning TroGen as a disruptive leader in programmable, off-the-shelf genetic medicines. IND filing is targeted for 2028, starting with ovarian cancer and melanoma

11:00 AM | SESSION 3 - MEDICAL DEVICE

Alleviate is the first and only organization that offers a fully integrated conservative management of musculoskeletal soft tissue joint pain used in the convenience of the home. It proposes therapeutic and preventative devices combined with an app-based guided recovery process, and captures pain and function patient reported outcomes. Evidence derived from the use of the app shows that a daily regimen of 10 minutes of guided exercises accomplished at home allows 85% of patients to achieve significant pain reduction. The data also demonstrates 50% to 70% improvement in pain at 6 weeks.

Exosystems is a digital healthcare company pioneering AI-driven digital therapeutics and electroceutical solutions to improve diagnosis, treatment, and monitoring for age-related and chronic conditions. By extracting digital biomarkers from bio-signals, we deliver personalized care through innovative technologies such as sarcopenia diagnosis support, remote treatment monitoring systems, and software-based digital therapeutics for exercise and rehabilitation. Our integrated platform combines AI, electroceuticals, and behavioral intervention software to bridge medical blind spots and overcome the limitations of traditional location-based care. With offices and operations focused on advancing healthy aging, Exosystems empowers clinicians and patients with scalable, accessible, and effective solutions that enhance outcomes across the full patient journey, from early detection to long-term management.

TissueForm is a seed-stage medical device company with a mission to provide like-for-like tissue implants for regenerative repair. TissueForm has developed an innovative implant to provide an immediate and effective repair for tissue damage and injury. Using human tissues to provide a repair is difficult, and therefore the industry has shied away, focusing instead on synthetic and metal implants. However, without using the blueprint of human tissue matrix, the body lacks the biological instruction set it needs to rebuild. TissueForm's innovative technology enables tissue repair with a human blueprint. Their injectable structural implant, Allovia, is transforming regenerative medicine by enabling the body to heal with a device made of the tissue it knows best — human tissue. While there are numerous areas of clinical need where this is critical, TissueForm has identified two markets where the structural aspect of the repair matters most: structural cosmetic fillers and knee cartilage repair.

1:00 PM | SESSION 4 - THERAPEUTICS

9Bio is redefining targeted cancer treatment by engineering therapies that strike tumors with precision while preserving healthy tissues – to provide patients with safer and more effective treatment options. Our computational structural biology platform integrates anatomical and biochemical insights to design highly selective therapeutics. This approach improves safety and efficacy by minimizing off-tumor effects and enables the development of novel drugs against previously underexploited targets. We are applying our platform to build a pipeline of next-generation targeted oncology therapeutics with a focus on antibody drug conjugates, including optimized versions of existing assets that failed in the clinic due to off-target toxicity, reducing development risk and maximizing value for patients.

KORTUC Inc. is a biotechnology company developing a novel hydrogen peroxide-based radiosensitizer that makes radioresistant tumors more responsive to radiotherapy. This simple, low-cost, intratumoral injection is administered immediately before radiotherapy, overcoming tumor hypoxia—one of the most fundamental causes of radiotherapy failure. KORTUC's technology has been tested in over 1,000 clinical cases in Japan and is now in late-stage development, including registrational Phase 2 trials led by the Institute of Cancer Research in the UK and India for locally advanced or recurrent breast cancer, with plans for rectal and cervical cancer trials in the US, EU, and Asia. Our product has the potential to benefit over 1.5 million patients worldwide, representing a $50B+ market. By improving outcomes while reducing treatment costs, KORTUC offers a transformative solution for cancer care, with anticipated launches in the US and EU by 2029.

Numiera Therapeutics Inc developing small-molecule drugs for oncology indications. We are targeting a critical step in cancer cell metabolism, CPT1. With orphan drug designation already awarded, on the basis of independently-replicated preclinical efficacy data from five different labs, and a comprehensive IND-enabling dataset on our lead molecule, including Phase I safety data in 226 human subjects, we are moving into clinical trials to evaluate our drug for the treatment of aggressive brain tumors. Our primary disease indication is glioblastoma (GBM). The standard-of-care chemotherapy drug only increases median survival time from twelve months to fifteen months, and new treatments are urgently needed. With our neuro oncology partners at Dana Farber Cancer Institute and across the country, our team is well-positioned to bring a new therapeutic option to this desperate patient population.

TroGen Therapeutics is building a next-generation gene therapy platform to overcome the major bottlenecks of cancer immunotherapy: lack of ideal tumor antigens, immunosuppressive tumor microenvironments, and systemic toxicity. Our Trojan Horse gene circuits act as smart decision-making units inside cancer cells, integrating proprietary tumor-specific promoters with programmable immune outputs. This enables precise recognition of tumor cells while sparing normal tissue, and the local release of potent therapeutic proteins (e.g., IL-12, CCL21, checkpoint inhibitors). Our platform, powered by high-throughput screening and AI optimization, achieves unmatched in vivo specificity and efficacy, even at partial delivery levels, and has outperformed gold-standard melanoma therapies in preclinical models. With broad modularity, our circuits can be adapted to diverse indications, positioning TroGen as a disruptive leader in programmable, off-the-shelf genetic medicines. IND filing is targeted for 2028, starting with ovarian cancer and melanoma

2:00 PM | SESSION 5 - R&D AND ENABLING TECHNOLOGIES

ORGANOPlus is a pioneering biotech company specializing in organoid-on-a-chip platforms to enable animal-free, human-relevant preclinical testing. Our proprietary Gut-on-a-Chip and Tumor-on-a-Chip technologies simulate key physiological environments—including villi, mucus layers, oxygen gradients, and immune co-culture—providing accurate, reproducible models for microbiome-based live biotherapeutics (LBPs) and oncology drug screening. ORGANOPlus partners with pharma, biotech, and CROs to deliver contract research services and out-license disease-specific chip models. With ongoing advancements in FDA/EMA-supported New Approach Methodologies (NAMs), our platform aligns with global regulations favoring animal replacement. In 2025, we are refining disease models and scaling SOP-based services, preparing for data-driven licensing and future SaaS expansion. ORGANOPlus is committed to ESG-driven growth—minimizing animal testing (3Rs), promoting accessibility in healthcare innovation, and adhering to transparent governance. With operations rooted in Korea and expansion plans targeting the U.S. and Europe, we aim to be a global leader in next-gen preclinical innovation.

RadaHaim is an innovative startup revolutionizing organoid research and development through a scalable mass production platform that brings standardization, efficiency, and affordability to the field. Organoids—3D cell cultures mimicking human organs—hold enormous promise for advancing drug discovery and personalized medicine, but adoption has been limited by cost, variability, and labor-intensive processes. RadaHaim overcomes these barriers by integrating robotics, bioengineering, and advanced imaging to streamline organoid generation and characterization. Our platform empowers researchers with reproducible models for reliable experiments and enables pharmaceutical companies to screen drugs faster and more cost-effectively. By making organoids accessible at scale, RadaHaim accelerates the development of safer, more effective treatments and drives a new era of innovation in healthcare.

Ronawk is a therapeutic enabling platform company delivering a physiologically relevant microenvironment replicating native tissue architecture and extracellular signaling, that improves the predictive power of preclinical models while minimizing translational disparities. Developed to address limitations of traditional 2D and scaffold-based culture systems, Ronawk's platform maintains native cell morphology, improves viability, and preserves phenotypic integrity. These capabilities make it especially well-suited for applications in cell therapy, regenerative medicine, predictive preclinical modeling and biologics manufacturing. By achieving sustained cellular function in physiologically relevant conditions, collaborators can accelerate therapeutic development timelines, improve translational accuracy, and generate richer, AI-compatible biological datasets. Ronawk's plug-and-play format integrates seamlessly into existing R&D and biomanufacturing workflows, permitting faster iteration, improved reproducibility, and reduced attrition throughout the development pipeline.

Thrive Bioscience, based in the Boston area, sells innovative, automated live cell imaging systems, powered by the Thrive IQ Platform, that enable biologists to harness modern data science techniques such as data mining and machine learning. Thrive systems replace microscopes because they automatically capture, organize, and analyze extensive data and image sets on living cells, empowering biologists and data scientists with actionable information for vastly improving experiments, insights and processes. The applications of Thrive's instruments include biomedical research, drug discovery/development, delivering cell therapies, assay development, imaging organoids, growing stem cells, IVF, and regenerative medicine. Thrive's growing base of customers capture big data and comparable data in 3D, time-series on live cells, colonies, and organoids in culture, resulting in significant increases in the efficiency, speed, and quality of their workflows. Customers include AstraZeneca, Harvard Stem Cell Institute, ThermoFisher, Battelle Institute, Massachusetts General Hospital, among others.

3:00 PM | SESSION 6 - THERAPEUTICS

BE Therapeutics is an early-stage biotech startup, developing technology to engineer functional brain and spinal cord tissue, (https://www.betherapeutics.com). Our mission is to engineer brain cortex replacement tissue to reverse age-related and other forms of damage as a treatment for stroke, traumatic brain injury and neurodegenerative diseases such as Parkinson's and Alzheimer's. Guided by how our human brains first develop, BE Therapeutics is engineering a precursor tissue that mimics normal developmental brain tissue, with the proper cell types, signaling cues, and structure, which allow this tissue to mature normally after transplantation, integrate with the host, and encode useful information for the patient. We have animal PoC data for our first neuronal transplant product and will identify a development candidate within 15 months. We are looking to close out a $5.5M seed round with an additional $2.7M of which $2.8M has been deployed by from Apollo Ventures and others.

Founded in 2024 as a spin-off from the University of Limoges, Curlim brings together three PhD scientists and a C-level Business person to tackle one of the biggest unmet needs in neurology: effective treatment for hereditary peripheral neuropathies. Our first mission: to develop a breakthrough therapy for Charcot-Marie-Tooth disease type 1A (CMT1A) — the most common hereditary neuropathy, caused by progressive demyelination and axonal damage. Through 3 proof of concepts on2 different animal models, we have been able to demonstrate robust results. OUr nanodrug CLM001 significantly improved motor nerve conduction velocities (MNCVs)and grip strength with a return to normal balance in both animal models. Remyelination and decrease of ROS coming back to normal levels were observed as secondary mechanisms.

Sensa Neuroscience is developing a novel drug candidate for the treatment of epilepsy, specifically targeting Developmental and Epileptic Encephalopathies (DEE). Our lead compound, SEN-126, is a proprietary analog of cannabidiol (CBD) that demonstrates superior pharmacokinetics and efficacy compared to CBD. While Epidiolex, a purified CBD formulation, has achieved widespread clinical use with annual sales exceeding $1 billion, it is often associated with adverse effects such as liver dysfunction, drug-drug interactions, gastrointestinal disturbances, and poor tolerability of twice-daily dosing in an oil-based formulation. SEN-126 is designed to address and minimize these limitations, offering providers a differentiated and more tolerable therapeutic option for epilepsy management. The ovary is the first organ to age in women, driving loss of fertility, menopause, and cascading declines in bone, cardiovascular, metabolic, and cognitive health. Despite its central role in health, and a $1 trillion dollar market opportunity, ovarian aging remains unaddressed by modern medicine.

TreasureBio's innovation will extend ovarian longevity through metabolic reprogramming and enhancement of cellular stress resistance. Our AI-powered discovery platform builds upon decades of multi-modal, multi-omics research from Harvard and Cleveland Clinic, and identified the first functional solution with exceptional capital efficiency. Our first product targets in vitro fertilization as a launchpad to extend reproductive longevity by improving egg and embryo quality. With a well-defined regulatory strategy and a stellar team, we are positioned to enter clinical trial within 18 months. By intervening ageing early, at its core, TreasureBio is unlocking a pipeline of therapies for age-related diseases, turning the promise of healthy aging into reality.

4:00 PM | SESSION 7 - THERAPEUTICS

Bilix, Inc. is a biotechnology company dedicated to developing innovative therapies for intractable diseases in inflammation and cancer, with the mission to improve human health one patient at a time for better and longer lives. Driven by courage and determination, Bilix takes on the challenge of finding cures for conditions long considered incurable. Our goal is to expedite drug development and provide therapeutic answers for patients in urgent need, while upholding a commitment to fairness and accessibility. By delivering cost-effective, equitable treatment solutions, Bilix strives to transform the lives of patients worldwide and bring hope where few options exist.

Elastrin Therapeutics Inc., headquartered in Greenville, SC, is pioneering breakthrough therapies targeting pathological arterial calcification to reverse and prevent cardiovascular disease. The company's platform leverages Flexibzumab, a proprietary humanized antibody that binds specifically to degraded elastin fibers, a root cause of tissue calcification. Elastrin's lead formulation, ELT-101, encapsulates a calcification-removing agent within time-release liposomes for precise, targeted delivery to disease sites using FDA-approved devices, minimizing off-target effects and procedure risks. Preclinical data underscore ELT-101's promise: Systemic intravenous administration in rat models demonstrated significant removal of aortic calcified deposits, while ex-vivo studies using both pig and human femoral arteries confirmed ELT-101's effective clearance of arterial wall calcification. Elastrin's therapy offers significant procurement and capital cost advantages over conventional treatments such as intravascular lithotripsy or surgery. With this innovative, less-invasive approach, Elastrin aims to restore natural vascular health by directly and selectively removing arterial calcification.

Inomagen Therapeutics, Inc. is a private, preclinical stage biotechnology company pioneering a gene therapy to improve the treatment of atrial fibrillation. Inomagen has intellectual property and proof of concept data for both the gene and the gene delivery system. Inomagen has a strong and experienced team of industry veterans and key opinion leading cardiovascular physicians to engage in management and advisory roles, including those with extensive domain experience in gene therapy, cardiology, AF therapeutics, medical device, clinical studies, and venture capital. The market size for Inomagen's gene therapy products is $10.2B.

pacDNA is a biotechnology company pioneering bottlebrush polymer–based delivery of oligonucleotide therapeutics. Our proprietary Brushield™ platform enables efficient delivery to tissues beyond the liver, overcoming one of the most significant barriers in the field. Brushield™ conjugates improve the pharmacokinetics, biodistribution, and stability of oligonucleotides, leading to enhanced efficacy and safety. Our lead programs target hidradenitis suppurativa (HS), a chronic inflammatory skin disease with high unmet need. Unlike antibody-based biologics, pacDNA's approach uses oligonucleotides, offering durable efficacy, reduced immunogenicity, and differentiation in indications with little oligonucleotide competition. Supported by NIH and DOD, pacDNA is advancing toward clinical proof of concept with a strategy that positions Brushield™ as both a therapeutic platform and a pipeline builder, with broad applications across dermatology, rare disease, oncology, and immunology.

9:00 AM - 4:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 2

Location: St. George C

Pitch Company				
9:00 - 9:50 AM SESSION #8 MEDICAL DEVICES	blend *Table #39*	BMI OrganBank *Table #28*	ISOTECH *Table #32*	
10:00 - 10:50 AM SESSION #9 MEDICAL DEVICES & DIAGNOSTICS	GIBionics™ NextGen Medical Devices *Table #22*	INSTA DIAGNOSTICS *Table #24*	LAON iMEDI *Table #2*	Spatial Surgical *Table #53*
11:00 - 11:50 AM SESSION #10 DIGITAL HEALTH	Chronicle *Table #11*	Geneial *Table #27*	gutz analytics *Table #52*	nSight Surgical *Table #34*
1:00 - 1:50 PM SESSION #11 MEDICAL DEVICES	DEEPSONBIO *Table #12*	PreTeL *Table #33*	TESORO IMAGING *Table #9*	
2:00 - 2:50 PM SESSION #12 DIGITAL HEALTH	AlgoDx *Table #21*	Embrace Prevention Care *Table #51*	NeuroVirt *Table #41*	WatchRx, Inc. HEALTH. DIGNITY. INDEPENDENCE *Table #42*
3:00 - 3:50 PM SESSION #13 DIAGNOSTICS	B4 RNA DETECTING CANCER BEFORE *Table #31*	Genialis *Table #49*	MLA DIAGNOSTICS *Table #8*	ONCODEA Cancer Code Innovations *Table #29*
4:00 - 4:50 PM SESSION #14 R&D AND ENABLING TECHNOLOGIES	ChromaTan Continuous Column-Free Chromatography *Table #6*	Gardn Bio *Table #43*	Manabio Programmable drug delivery *Table #50*	medovation. CLINICAL RESEARCH *Table #40*

9:00 AM | SESSION 8 - MEDICAL DEVICE

blendhealth.ai is advancing the future of hypertension care with its cuffless continuous blood pressure monitoring for the upper arm. With strong IP portfolio and deeptech approach using a novel multi-wavelength approach aided by AI models based in biomechanics, the device has been tested over nearly 100 subjects. Led by a very strong management team that has brought several medical devices to market, the company is well positioned to meet an unmet need in a $4B target market of $4B for hypertension management and predictive analytics to predict cardiovascular events and provide actionable insights. Blend is currently raising its second round (seed round) and is on target to start clinical validation with its commercial device and file for FDA clearance in 2026.

BMI OrganBank is developing medical devices to eliminate the waitlist for lifesaving kidney transplants through better kidney assessment, preservation and transport technologies. BMI developed their unique flagship product for kidney preservation in partnership with Duke University transplant surgeons and subsequently published promising preclinical data in a peer-reviewed journal. The FDA recently granted BMI OrganBank a Breakthrough Device Designation. We have completed several presubmisions with FDA and plan to initiate a clinical study early next year. BMI has received non-dilutive funding from the NIH, NSF, ARPA-H and DOD and investor funding from mulitiple angel groups with deep medical device expertise.

IsoTech Ltd is developing a novel wearable therapeutic medical device that stabilises blood pressure on standing to help older adults avoid dizziness and falls from orthostatic hypotension. The device guides a 30–60-second, on-demand isometric muscle contraction via a discreet retractable tether with visual and haptic cues, turning an evidence-based counter-manoeuvre into a simple, repeatable action without drug side effects. A completed proof-of-concept clinical study demonstrated clinically meaningful blood-pressure stabilisation in a substantial subset of patients with high usability and no unwanted adverse effects. The next phase is straightforward but execution-critical: design-for-manufacture and verification, Class I UKCA/CE technical documentation and light-touch QMS, tooling and pilot build, and a KOL-led seeded launch while preparing reimbursement pilots and strategic licensing options. Protected by patents on mechanism and form factor, ISO-101 aims to become the category-defining, real-time therapy for OH, improving independence for ageing populations and reducing falls-related costs for health systems at scale.

10:00 AM | SESSION 9 - MEDICAL DEVICES & DIAGNOSTICS

GI Bionics has developed fecoBionics, a breakthrough technology platform for diagnosing and treating defecation disorders, including fecal incontinence and constipation - conditions poorly addressed by current solutions. fecoBionics integrates three diagnostic procedures into one device, enabling accurate assessment to move from specialty centers into GI and OBGYN clinics. The platform is FDA 510(k) cleared, supported by a strong IP portfolio, and designed to fit seamlessly into existing reimbursement frameworks without requiring capital investment from clinics. To date, more than $15 million has been invested in development, validation, and clinical trials. The market for defecation disorders remains significantly underserved, with high demand for effective innovation. GI Bionics' founding team brings a proven track record of successfully developing and exiting medical device companies, positioning the company to transform care and capture a substantial market opportunity.

Instadiagnostics' mission is to bring laboratory quality blood/urine/saliva/swab tests to the point of care on a single, user-friendly diagnostic system. We envision a future where every patient receives timely, accurate, and comprehensive healthcare within a single visit. Our product is a diagnostic technology platform consisting of a compact analyzer (InstaAnalyzer) that runs disposable, self-contained, multi-biomarker cartridges (InstaCartridges). The InstaAnalyzer will perform lab-quality immunoassays, molecular tests, chemistry assays, and blood cell counts in a fully automated manner, minimizing user errors by requiring only the placement of an unprocessed sample on an InstaCartridge, followed by its insertion into the InstaAnalyzer. This will improve patient outcomes by reducing loss to follow-ups, delay in diagnosis of infectious diseases, and timely management of chronic diseases. It could eventually reduce the overall cost of healthcare by early disease diagnosis, treatment, and management.

LAON MEDI Inc., leveraging the AI technology of its parent company LAON PEOPLE Inc., is developing next-generation digital dental solutions in auto cephalometric diagnosis, clear aligner treatment planning, and 3D printing workflows. Its flagship product, Laon Ortho, is designed for orthodontic professionals, automating time-intensive processes with precision by analyzing lateral X-rays, 3D scans, and CBCT data. By combining AI-powered automation with clinical expertise, LAON MEDI streamlines semi-automatic clear aligner setup and supports both indirect and direct 3D printing applications. The result is faster, more accurate, and more accessible orthodontic care that empowers clinicians to deliver better treatment outcomes.

Spatial Surgical is a medical device company developing the Aureon, a novel surgical system that combines a first-in-class tissue cutting laser with multimodal visualization technology into a single handpiece. By integrating robotic technologies into a novel tissue-cutting device, we are bridging the surgery innovation gap for the millions of patients who cannot be addressed by current surgical robots and still undergo open surgery today. The laser's novel wavelength allows for rapid, bloodless incisions while the multimodal visualization technology offers robotic-assisted visualization capabilities. Our target market represents an approximately $20 billion opportunity and comprises the colorectal, gynecology, and obstetrics specialties.

11:00 AM | SESSION 10 - DIGITAL HEALTH

Chronicle

Chronicle provides optimized medical information at point-of-care because the right data leads to the right decisions. Our web-based, SOC-2-compliant app displays medical information optimally for clinicians, patients, and analysts. Chronicle saves hours on chart review each day, facilitates guideline-compliant care, and enables rapid quality analysis. Our user-interface shows information chronologically by diagnosis, provides patient-specific guidance at point-of-care based on expert guidelines, and includes querying and basic statistical functions so that customers can access and analyze their data for quality improvement. Chronicle's monthly subscription pays for itself the first day by saving time on chart preparation, review, and abstraction. Chronicle is free to customers' patients so that doctors and patients can easily view the same information for enhanced shared decision-making.

Geneial

Geneial is building the AI-ready data infrastructure powering next-generation precision medicine. Our platform unifies fragmented patient data, automating consent, cleanup, and engagement to deliver clean, reusable datasets at scale. With Advocate, our patient-first mobile app, and Bridge, our researcher platform, we achieve up to 7x higher participation than legacy systems. Our AI scientists analyze this data, generate novel hypotheses, and deliver actionable insights, accelerating discoveries and enabling pharma to optimize endpoint selection, inclusion criteria, and recruit engaged patient cohorts faster. Trusted by NIH and ARPA-H with over $4.5M in non-dilutive funding, Geneial is deployed across registries with Baylor College of Medicine, UNC, Pitt, and Texas Children's Hospital. Starting in rare disease—where need and impact are greatest—we are scaling toward enterprise integrations across payers, biopharma, and health systems, driven by a team with multiple successful exits in AI-driven drug discovery, genomics, and healthtech, unlocking system-wide data liquidity.

gutz analytics

nSight Surgical

nSight Surgical is the first, truly objective health care record. Our video based artificial intelligence system is a consistent observer reporting efficiency, quality, and cost data to health centers. Our non discoverable data sits parallel to the current electronic medical record, which stems solely from subjective and incomplete reporting data. We integrate with current EMR systems and we are capable of reporting our data to that system and extracting data from it for analysis. We deploy camera networks to:

- passively acquire data in the operating room
- and deliver data back to OR staff via interface when and where they need it
- that we real time process in our AI stack
- that data spans three key areas: efficiency, cost, and quality

1:00 PM | SESSION 11 - MEDICAL DEVICES

DeepsonBio is a therapeutic ultrasound specialist pioneering non-invasive solutions for chronic and severe diseases. By leveraging state-of-the-art low-intensity ultrasound technologies, the company develops innovative devices that safely and accurately deliver targeted therapy to the human body, including applications in brain diseases and tumors. Its proprietary Sono DDS technology enhances drug delivery by reducing dosage requirements, minimizing toxicity, and improving safety and efficacy. Through customized ultrasonic profiling and device designs optimized for specific treatment areas, DeepsonBio is advancing clinical trials to validate its therapies and bring them to hospitals and general users. With a mission to transform treatment standards, DeepsonBio is driving innovation at the intersection of ultrasound, pharmaceuticals, and patient care.

PreTeL has developed bedside clinical decision support monitoring system that determines who will deliver in the next 7 days - allowing for the administration of antenatal corticosteroid to significantly reduce the occurrence and severity respiratory distress syndrome, undeveloped brain and intestinal tract, permanent hearing and vision loss, and death. PreTeL's wearable sensor array and ML analytics can also be applied to other indication such as Dosing Guidance for Pitocin/oxytocin induction delivery and elimination of false contractions during fetal monitoring.

Tesoro Imaging S.L. is a spin-off of the Institute of Molecular Imaging Instrumentation (i3M) of the Spanish National Research Council and the Polytechnic University of Valencia, Spain. The MRILab research group is the world-reputed team behind the technical and industrial viability of our products. Tesoro's BRAIN device offers a new paradigm in MRI equipment:100% Portable, Plug and Play Operation, High Resolution Imaging at an Unmatched Speed, responding to unmet needs in healthcare. It is a Low-Field, Low-cost system, operating at just 87 mT, delivering highly detailed neuroimages thanks to advanced spatial coding algorithms.This allows screening for structural abnormalities and basic pathology assessment in areas previously unaccessible to MRIs. Its innovative design shifts the paradigme from expensive hardware to efficient methodology, addressing rapidly escalating healthcare costs worldwide.

2:00 PM | SESSION 12 - DIGITAL HEALTH

AlgoDx is pioneering ML-driven clinical decision support solutions with a strong focus on sepsis management, enhancing patient outcomes and reducing healthcare costs across settings – from the ED through the continuum of care. NAVOY CDS® is our FDA-cleared solution helping U.S. health systems improve their CMS SEP-1 sepsis bundle compliance through early sepsis detection and tracking patients' deterioration. The software comes with a powerful suite of tools that empower hospitals looking to boost their quality and safety ratings, and strengthen their bottom line.

Embrace Prevention Care is a tech-enabled service company providing value-based care to dementia patients. Our virtual preventive care model reduces hospital days by 30% for older adults with dementia and other chronic conditions and keeps them out of the nursing home. We were selected to provide our care in Medicare's 8-year GUIDE program that offers this care at no cost to patients and pays Embrace monthly. Medicare's protected Fee-For-Service market will allow us to collect the clinical outcomes and $2500/year net savings data that will support our offering this service to at-risk payors and providers such as Medicare Advantage Plans. We are providing GUIDE care to patients in 6 states and are raising a $4M Seed round to expand to 12 states and achieve a $5MM ARR by the end of 2026. We are building a robust referal network with a low customer acquisition cost.

NeuroVirt is a revolutionary XR rehabilitation solution that transforms patient recovery and empowers physiotherapists with smarter, data-driven care. By combining engaging therapy, precise compensation control, and accurate remote monitoring, NeuroVirt enables healthcare providers to:
- Deliver 15x more therapy without requiring additional staff or resources
- Accelerate recovery by 30% through more effective, consistent training
- Boost patient adherence by 200% with motivating, gamified exercises
- Ensure exercise accuracy with advanced compensation control, giving clinicians confidence that movements are performed correctly
- Access the most comprehensive impairment and improvement metrics available in the market
- Monitor patients remotely to extend care beyond the clinic

Beyond rehabilitation, NeuroVirt helps providers reduce falls, lower hospital readmissions, shorten time to discharge, cut costs, and increase revenue - making it not only a clinical innovation, but also a sustainable business solution.

WatchRx provides digital health solution for Remote Patient Monitoring and Chronic Care management. Our preventive care solution identifies patients with critical needs, guide them to follow care plans and take timely actions to prevent hospital admissions. Our patented solution includes a smartwatch app (Android, Apple or Pixel), a patient app, a caregiver app, and an AI-based care coordination SaaS platform. Our smartwatch provides visual medication reminders with name, image, dosage and personalized voice instructions, voice/video calls, text, live GPS tracking and fall detection. Our caregiver app provides smart alerts, reports, vitals collection, automatic time tracking, voice assisted helpline, surveys, and responses. Our AI powered care coordinator platform provides smart actionable alerts and automatic triage that the nurses can act upon to prevent ER visits and hospital admissions. WatchRx has efficient workflows for nurses, integrated voice/video calls on the watch and caregiver app that generates critical alerts to care team.

3:00 PM | SESSION 13 - DIAGNOSTICS

B4-RNA is developing a liquid biopsy test for early cancer detection based on a proprietary RNA repair and sequencing method that allows us to sequence stable nicked tRNAs, unlocking a novel biomarker category. Our technology, which combines a repair and sequencing kit and an online AI-based analysis platform, does not require deep sequencing and thus allows us to develop an accessible NGS-based diagnostic tool. We are targeting Lung, Colon and Ovarian cancers focusing on the US market. We're currently in a preclinical stage expecting preliminary validation results in Q4 2025, and we're looking for investment that would help us both move into clinical trials in 2026 and set up a presence in the US.

Genialis is a precision oncology company revolutionizing drug development and patient care with an entirely new approach to biomarkers. Genialis has built the first RNA-based AI foundation model of cancer biology. Trained on billions of data points from ~1 million tumor samples representing globally diverse patients, this large molecular model (LMM) (colloquially called the "Supermodel") yields next-generation biomarkers to help pharma succeed in drug development, avoid long and costly clinical trial failures, and win the race for First-in-Class and Best-in-Class drugs. The latest Genialis biomarker, Genialis krasID, is being validated by multiple top 20 Pharma and industry leading diagnostics companies. Genialis is raising additional capital ahead of its Series B to deepen its pharma traction, grow its biomarker product portfolio, and expand into diagnostic/provider market segments. These milestones will position Genialis to disrupt the $60+ Bn oncology biomarkers market, and to fulfill its promise to transform medicine with data.

MLA Diagnostics is a molecular diagnostics developer focusing on the creation of enhanced test solutions for oncological application. Our current product ZerO combines molecular (DNA methylation) data of tumor tissue , clinical and pathological parameters to risk-stratify early stage melanoma patients and effectively guide treatment decisions. Through our ultra-sensitive/fully quantitative and proprietary PCR test technology, algorithm and software, we gather, analyze and present actionable data to clinicians. We're currently raising 4M to fund our 2026/2027 US clinical validation strategy, realize reimbursment and initiation of our LDT services. Additional note: We also have an active R&D program that, through multi-omic biomarker discovery and validation projects, aims to develop new applications (diagnostic, prognostic, predictive and monitoring tests) in melanoma as well as other solid cancers. These project are fully funded though non-dilutive sources.

Oncodea is built to solve the problems of early cancer detection. With just a few drops of blood, we can reveal the earliest presence of cancer as early as stage 0 and even before the symptoms appear. We're making cancer screening as routine and accessible as a glucose test. We stand for 3 simple ideas: highly accurate, accessible and affordable We have a larger vision to one day become the platform model for early disease detection. Not just cancer but any diseases relating to aging.

4:00 PM | SESSION 14 - R&D AND ENABLING TECHNOLOGIES

ChromaTan has developed BioRMBTM the first-ever, continuous column-free, single-use, and steady-state chromatography platform, based on the Real Moving Bed principle that provides significant improvements in recovery, productivity, and product purity, while reducing resin consumption and downtime compared to conventional column chromatography for manufacturing of biologics, gene therapies and mRNA. The company holds multiple patents on the platform and has a number of pilot units sold in the field. Our clients include Large Biopharma companies, CDMOs and academia

Gardn Bio has developed the most compute- and data-efficient platform for complete RNA design available, allowing in-vivo ready sequences to be created on personal laptops. Our tools can rapidly optimize both coding and non-coding RNA for a nearly unlimited number of functions, including expression, manufacturability, stability, specificity, and immune evasion. These tools offer the benefits of a deeply integrated AI technology while bringing the cost of training and inference to $0, opening up a fundamentally new space of collaboration possibilities. This extreme efficiency also allows the integration of diverse datasets into the design process, simplifying the path from in-vitro testing to in-vivo validation. In addition to this design studio, Gardn has also developed a suite of programmable RNA mechanisms that confer different logical behaviors when plugged into arbitrary therapeutics. These mechanisms perform across mRNA, circRNA, and saRNA modalities, positioning Gardn to offer complete RNA medicines for the price of software.

Mana.bio leverages AI/ML to design novel non-viral ex-liver cell-specific RNA delivery solutions. Mana Bio is a seed-stage biotech company leveraging data, machine learning, and high throughput screening to design novel LNPs for extrahepatic delivery of nucleic acid therapeutics and vaccines. Mana was founded by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning, and software development. Mana built predictive AI models and achieved novel IP-protected in vivo results, including lung-specific delivery of mRNA. The company is now open to leveraging this technology platform for collaborations with biotech and pharma companies to optimize formulations for cell-specific delivery of a wide range of payloads, including mRNA and CRISPR gRNA

Medovation Clinical Research is an Integrated Research Organization that partners with community-based physicians to launch and manage clinical trials within their existing practices. As the industry accelerates drug/device development, the number of clinical trials is far outpacing the supply of qualified investigators. With fewer than 10% of U.S. physicians engaged in research, patients—especially in underserved communities—are missing out on access to cutting-edge treatments. Medovation addresses this gap by equipping "naive" investigators—physicians new to research—with the infrastructure, training, staffing, and regulatory support they need to become high-performing research sites. Our model is scalable, efficient, and designed to deliver value to Sponsors, physicians, and patients. In our first 18 months, we launched 9 sites, activated 14 studies, built a robust trial pipeline, and generated over $600K in revenue. We're redefining access to innovation—empowering more physicians to participate in research and helping more patients benefit from tomorrow's medicine, today.

9:00 AM - 4:50 PM | INVESTOR PANEL & WORKSHOPS

Location: St. George C

Presenters	
9:00 - 9:50 AM **NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS**	**Rick Berenson,** Executive Committee Member, Mass Medical Angels (MA2), Managing Director of Venzme Catalyst
10:00 - 10:50 AM **TALES FROM THE ROAD** *Biotech and MedTech Innovators on their Fundraising Journey*	**Greg Mannix,** VP of International Business Development, Life Science Nation **(Moderator)** **Cristian Atria,** Founder & CEO, nView Medical **Susan Conover,** CEO, Piction Health **Patrick Jiang**, CEO, InGel Therapeutics, Inc. **Ana Maiques**, CEO, Neuroelectrics
11:00 - 11:50 AM LIFE SCIENCE NATION Connecting Products, Services & Capital **LSN BD ASSIST** *Your Global Matching and Partnering Engine*	**Dennis Ford,** Founder & CEO, Life Science Nation; Creator of RESI Conference Series **Karen Deyo,** VP of Product, Israel Business Development, Life Science Nation
1:00 - 1:50 PM MSQ VENTURES **AI-DRIVEN TRANSFORMATION IN LIFE SCIENCES**	**David Berry,** Managing Partner, Averin **Jacob Oppenheim,** Venture Partner at RA Capital (RAVen) **Lovisa Afzelius,** General Partner at Flagship Pioneering **Ethan Than,** Global Digital/AI Strategic Partnerships & Transactions (BD&L), Sanofi **Nikhil Mutyal,** Head of Search and Evaluation, Respiratory and Immunology, AstraZeneca **Rehan Huda,** Co-Founder, Chairperson, Board of Directors and CEO, GNQ Insilico
2:00 - 2:50 PM VENTURE VALUATION GLOBAL VALUATION SERVICES **COMPANY VALUATION FOR FUNDRAISING**	**Patrik Frei,** Founder & CEO, Venture Valuation AG, Switzerland
3:00 - 3:50 PM mosaic **ACCELERATING EARLY-STAGE DRUG DISCOVERY**	**Eric Furfine,** CEO & CSO, Mosaic Biosciences
4:00 - 4:50 PM LIFE SCIENCE NATION Connecting Products, Services & Capital **BRANDING & MESSAGING OVERVIEW**	**Greg Mannix,** VP of International Business Development, Life Science Nation **Max Braht,** Director of Business Development, Life Science Nation

9:00 AM | NEW MODEL FOR EVALUATING AND INVESTING IN EARLY-STAGE ASSETS
A BREAKTHROUGH FRAMEWORK FOR SMARTER LIFE SCIENCE INVESTING

Rick Berenson, Managing Director of Venzyme Catalyst, introduces a revolutionary way to evaluate early-stage biotech and medtech ventures. Too often, investors rely on "gut" decisions about risk and valuation, while entrepreneurs struggle to communicate their company's true merit—leading to optimistic expectations and missed opportunities. This workshop unveils a powerful framework for improving returns by mapping and managing the entire risk stack, offering investors a clearer, more systematic approach to evaluating strengths, weaknesses, and drivers of success. Whether you are seeking to sharpen your own decision-making or help your team align more effectively, this session will provide insights that immediately change how you view early-stage opportunities. Join us to discover why this breakthrough model is reshaping the rules of life science investing.

Rick Berenson, Executive Committee Member, Mass Medical Angels (MA2), Managing Director of Venzme Catalyst

Rick Berenson will present a practical approach for how family offices can assess early-stage biotech without building a whole internal diligence team. As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the "wisdom of an expert crowd." He'll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.

LIFE SCIENCE NATION
Connecting Products, Services & Capital

10:00 AM | TALES FROM THE ROAD
BIOTECH AND MEDTECH INNOVATORS ON THEIR FUNDRAISING JOURNEY

The industry has quickly adapted to a "new normal" – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

Greg Mannix, VP of International Business Development, Life Science Nation **(Moderator)**

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

Cristian Atria, Founder & CEO, nView Medical

Cristian is a healthcare entrepreneur with more than twenty years experience in product development and commercialization. He founded nView medical after a successful career with GE Healthcare where he developed and launched three major platform products, ran an acquired business in computer aided surgery, and turned around a product line from 50% decline to 30% growth. Cristian was responsible for the product launch of Fiagon's (Berlin, Germany) navigation system in the Americas and oversaw new product development of HealthTronics's (Austin, TX) image guided cryotherapy products. Cristian has authored more than ten patents and various publications. He holds two Masters of Science in Engineering (Centrale-Supelec in Paris, France and Politecnico di Torino in Italy), an MBA from Boston University and a certificate in Entrepreneurship from MIT. Cristian is passionate about innovation. He spends his free time with his family or in the outdoors climbing, mountain biking, and skiing.

Susan Conover, CEO, Piction Health

Susan Conover is the co-founder and CEO of Piction Health, an AI-powered virtual dermatology practice that delivers fast, affordable, and insurance-covered skin care across six U.S. states. She is building the first AI-native dermatology operating system — empowering clinicians with "superpowers" by removing administrative burden, improving diagnostic accuracy, and scaling access to expert care. Previously, Susan worked at the intersection of technology, healthcare, and design, and she is passionate dermatology as she's been diagnosed with melanoma 3 times and struggled to access the care she needed.

Patrick Jiang, CEO, InGel Therapeutics, Inc.

Patrick Jiang is the Cofounder & Chief Executive Officer of InGel Therapeutics, a clinical-stage biotech company developing bioengineered cell therapies for patients suffering from Retinitis Pigmentosa. He earned his Bachelor's degree from Northwestern University and began his career as an early employee focused on business development at Horizon Therapeutics. After Horizon's acquisition by Amgen, Patrick went on to pursue an MBA at Harvard Business School, where he co-founded InGel Therapeutics with Harvard Professor Michael Young, a leading scientist in human retinal stem cells and biomaterials. Influenced by his grandmother, who lost her sight in her 50s due to macular degeneration, Patrick is committed to developing medicines that will make a difference for patients with limited options.

Ana Maiques, CEO, Neuroelectrics

Ana Maiques is CEO and Co-founder of Neuroelectrics, a Barcelona- and Boston-based company developing non-invasive brain stimulation devices to treat neurological disorders. Recognized among Europe's most inspiring women in tech, she is also President of EsTech and a member of the European Innovation Council Advisory Board. Under her leadership, Neuroelectrics has advanced breakthrough technologies such as the Starstim device, securing FDA approval for remote treatment of depression and raising $17.5M for clinical trials in epilepsy and depression. A strong advocate for gender diversity in STEM, Ana has received honors including the EU Prize for Women Innovators and Goldman Sachs' Most Exceptional Entrepreneurs award.

11:00 AM | LSN BD ASSIST:
YOUR GLOBAL MATCHING AND PARTNERING ENGINE

Fundraising in life sciences is a numbers game. Most programs stop at pitch training, but winning capital takes a 9 to 18 month global campaign with disciplined outreach and relentless follow up. LSN BD Assist runs that campaign for you. Built on four pillars — matching, messaging, meetings, and follow up — we connect you with the right partners by stage, product, and strategic fit while filtering out mismatches. From a curated database of 7,000 investors and licensing partners, we build a 600 to 800 target list, integrate it in Salesforce, update it daily, and drive the outbound so you can focus on science. More than 400 startups have used BD Assist to raise over 5.4 billion dollars.

Dennis Ford, Founder and CEO, Creator of RESI Conference, Architect LSN Labs

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of The Peddler's Prerogative and The Fund Manager's Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive's Fundraising Manifesto which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO which is now offered to help launch and fund startups into the global life science arena.

Karen Deyo, VP of Product, Israel Business Development, Life Science Nation

Karen Deyo is the VP of Product at Life Science Nation, responsible for new product development and LSN's educational content. In addition to her role as VP of Product, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. She started out at LSN as part of the investor research team, speaking to investors and learning their investment mandates. Karen utilizes her experience speaking with investors as well as her scientific background to help startups translate their science and prepare for their global partnering campaigns. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.

1:00 PM | AI-DRIVEN TRANSFORMATION IN LIFE SCIENCES
BIOPHARMA, BIG PHARMA, AND INVESTOR PERSPECTIVES

Artificial Intelligence (AI) is transforming drug discovery, development, and commercialization, offering both unprecedented opportunities and complex challenges. This 50-minute panel unites leaders in AI strategy, data science, digital innovation, and early-stage investment to explore the future of healthcare innovation. Discussions will highlight how Big Pharma and biopharma are leveraging AI to accelerate drug discovery, refine clinical trial design, and streamline regulatory processes. Panelists will examine the balance between building internal AI capabilities versus partnering with startups, vendors, and academia, as well as how investors evaluate AI-driven ventures. Key hurdles—such as data silos, compliance, talent gaps, and patient privacy—will also be addressed. The session will spotlight areas of highest ROI, from target identification to real-world evidence, while exploring emerging disruptions like generative AI, digital therapeutics, and virtual trials. Attendees will gain a strategic perspective on collaboration models, investment trends, and the realities of adopting AI in life sciences.

VENTURE VALUATION
GLOBAL VALUATION SERVICES

2:00 PM | VENTURE VALUATION WORKSHOP
COMPANY VALUATION FOR FUNDRAISING

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland

Dr. Patrik Frei is the founder and CEO of Venture Valuation AG, a company he established in 1999 to provide independent valuation services for high-growth industries. His first client was Novartis Venture Fund, and he has since conducted over 450 valuations for investors, biotech, pharma, and medtech companies. Patrik earned his degree from the University of St. Gallen and completed his PhD at EPFL Lausanne, focusing on the assessment and valuation of high-growth companies. He has served on the boards of Ineo, Aventron AG, and Ophthalmopharma, where he successfully out-licensed a portfolio of products. His articles have been published in journals such as "Nature Biotechnology" and "Chimia," and he has authored business publications. Dr. Frei also lectures on valuation at institutions like Seoul National University, EPFL Lausanne, and the University of St. Gallen, offering workshops globally.

mosaic

3:00 PM | ACCELERATING EARLY-STAGE DRUG DISCOVERY
HOW CRO PARTNERSHIPS FUEL STARTUPS' PATH TO SUCCESS

Early teams live or die by how well they translate scarce capital into decisive biology. In this 50-minute workshop, Mosaic Biosciences – a therapeutics-focused Partnered Research Organization (PRO) – shares practical playbooks for using external discovery partners to compress timelines, sharpen decision-making, and preserve runway. We'll cover when to bring on a CRO/PRO across funding stages, how to scope work that drives go/no-go inflections, and ways to structure SOWs and budgets for flexibility without losing accountability. Through candid case studies and interactive Q&A, we'll dissect common traps (over-dependence, scope creep, misaligned incentives) and show how the right partnership can raise the scientific bar while lowering operational load for lean teams.

You'll leave with:

- A simple "partner fit" scorecard and questions to pressure-test providers
- Negotiation tips and SOW guardrails that protect IP, timelines, and budget
- A milestone-based budgeting map from pre-seed to Series A
- Practical frameworks for choosing discovery strategies (e.g., in vivo vs. in vitro) based on program risk and speed

Hosted by Mosaic Biosciences – engineers, assay builders, and "drug hunters" dedicated to helping founders reach their next value-inflection faster.

Eric Furfine, CEO & CSO, Mosaic Biosciences

Eric brings experience in leadership roles in biotechnology and pharmaceutical companies to the role of Chief Executive and Scienti Office at Mosaic. He is a visionary leader and drug hunter in the biotech and pharmaceutical industry. As CSO and President R&D at Eleven Biotherapeutics, his leadership drove an IPO that financed Phase 3 clinical studies and a lucrative licensing deal a second therapeutic asset. His building the Adnectin protein therapeutic discovery platform at Adnexus resulted in the acquisiti of the company by BMS, where subsequently five adnectins were advanced into clinical studies. As VP Preclinical Development Regeneron, he played pivotal roles in developing game-changing drugs, such as Eylea. Eric received his PhD in Biochemistry fro Brandeis University

LIFE SCIENCE NATION
Connecting Products, Services & Capital

4:00 PM | BRANDING & MESSAGING OVERVIEW
THE STORYTELLING FRAMEWORK: 4 STORIES, 1 NARRATIVE - TRANSFORMING SCIENCE INTO INVESTOR-READY PITCHES

Scientific innovation is only as powerful as the story that brings it to life. In this hands-on workshop, discover the storytelling framework that has helped founders turn complex science into compelling, investor-ready narratives. We'll go beyond the data to connect your science and business strategy to real-world impact, ensuring that your company's mission resonates with every stakeholder, from investors to partners. What You'll Learn - At the core of successful investment pitches and brand building is the ability to weave together four essential narratives:

- The Founder Story – Articulate your personal connection to your mission. We'll help you illuminate the "why" behind your journey, making your passion and commitment clear and authentic to others.
- The Technology Story – Translate technical breakthroughs into accessible, inspiring language. Learn how to illustrate how your innovation is truly better, faster, cheaper, and more disruptive than what's come before.
- The Patient Story – Humanize your impact. Through the lens of real patient scenarios, you'll learn to convey urgency and demonstrate meaningful, tangible benefits—connecting emotionally with your audience.
- The Business Story – Frame your business case with data-driven clarity. Ground your narrative in key metrics—market size, sales traction, IP portfolio—to present an investment-worthy opportunity.

Who Should Attend:
This session is ideal for founders, scientists, and startup teams in biotech, medtech, and other innovation-driven fields who want to refine their storytelling skills and enhance their fundraising prospects.

Greg Mannix, VP of International Business Development, Life Science Nation

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

Max Braht, Director of Business Development, Life Science Nation

At Life Science Nation (LSN), Max leads the Global Business Development team and directly oversees the U.S. East Coast region, where he is based. He is responsible for assisting early-stage companies across the life sciences — including therapeutics, devices, diagnostics, and digital health — in expanding beyond their local regions and connecting with global investors through participation in LSN's Redefining Early Stage Investments (RESI) conference and the use of LSN's curated Investor Platform. Max holds an MBA from Oklahoma State University, as well as an MiM and an MSc in Artificial Intelligence & Digital Technology Management from the Burgundy School of Business in Lyon, France.